Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 1 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 A Phase I Study to Determine the Relative Bioavailability of Various Formulations of 
GDC-0134 in Healthy Female Subjects of Non- Childbearing Potential  
 
    
Protocol GP40957 
 
Covance Study 8398091 
 
IND 125737 
 
Version Number 1 
 
for 
 
Genentech, Inc. 
1 DNA Way  
South San Francisco, California 94080-4990 
    
by 
 
Covance Early Clinical Segment  
3402 Kinsman Boulevard 
Madison, Wisconsin 53704 
 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 2 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 STUDY IDENTIFICATION 
Sponsor Genentech, Inc.  
 1 DNA Way  
 South San Francisco, California 94080-4990 
 
Sponsor’s Study Contact Sravanthi Cheeti, B.Pharm., MS,  
Clinical Pharmacologist  
 Genentech, Inc. 
 1 DNA Way  
 South San Francisco, California 94080-4990 
 Sponsor’s Medical Monitor  William Cho, M.D., Ph.D. 
 Genentech, Inc. 
 1 DNA Way  
 South San Francisco, California  94080-4990 
 Study Site Covance Clinical Research Unit  
 1900 Mason Ave, Suite 140 
 Daytona Beach , Florida 32117 
  Covance Clinical Research Unit  
 1341 W. Mockingbird Lane, Suite 200 E, 
 Dallas, Texas 75247 
 Principal Investigator  Hugh Coleman, D.O.  
 Covance Clinical Research Unit  
 Daytona Beach, Florida  
 hugh.coleman @covance.com 
  T. Alexander King, M.D. 
 Covance Clinical Research Unit  
 Dallas, Texas 
 alex.king@covance.com 
 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 3 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 Study Institutional 
Review Board  MidLands Independent Review Board 8417 Santa Fe Drive, Suite 100 Overland Park, Kansas 66212 
 Main Clinical L aboratory Laboratory Corporation of America  
     4200 N 29
th Ave 
     Hollywood, Florida  33020-1016 
      Laboratory Corporation of America  
     7777 Forest Lane Building C350      Dallas, Texas 75230 
 Bioanalytical Laboratory  Covance Laboratories Inc.  
 3402 Kinsman boulevard 
 Madison, W isconsin, 53704 
 Protocol b iostatistician  Emma Warriner , M.Sc. 
 Covance Early Clinical Biometrics  
 emma.warriner@covance.com  
 Protocol pharmacokineticist  Sarah Thorn, B.S. 
 Covance Clinical Pharmacology Services 
 sarah.thorn@covance.com  
 Protocol medical writer  Edward Bowen , Ph.D. 
 Covance Global Medical Writing  
 edward.bowen@covance.com  
Clinical Protocol 
Covance Study 8398091 CONFIDENTIAL 
Protocol GP40957 
 
 
Final:  19 December 2018 Page 4 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 TABLE OF CONTENTS 
 
1 SYNOPSIS ...................................................................................................................... .. 11  
2 INTRODUCTION ............................................................................................................ 13  
2.1 BACKGROUND .................................................................................................. 13  
2.2 OVERVIEW OF GDC-0134 CLIN ICAL DEVELOPMENT .............................. 14  
2.3 CLINICAL PHARMACOKINETICS OF GDC-0134 ......................................... 15  
2.4 STUDY RATIONALE ......................................................................................... 16  
2.5 DOSE RATIONALE ............................................................................................ 16  
3 STUDY OBJECTIVES AND CORRESPONDING ENDPOINTS ................................. 17  
3.1 PRIMARY OBJECTIVE ...................................................................................... 17  
3.2 SECONDARY OBJECTIVES.............................................................................. 17  
3.3 EXPLORATORY OBJECTIVES ......................................................................... 17  
3.4 ENDPOINTS ........................................................................................................ 17  
3.4.1  PHARMACOKINETIC ENDPOINTS ............................................... 17  
3.4.2  SAFETY ENDPOINTS ...................................................................... 18  
4 STUDY DESIGN.............................................................................................................. 18  
4.1 DESCRIPTION OF THE STUDY ....................................................................... 18  
4.2 RATIONALE FOR STUDY DESIGN ................................................................. 22  
4.3 RATIONALE FOR SUBJECT POPULATION ................................................... 22  
4.4 RATIONALE FOR EXPLORATORY ASSESSMENTS .................................... 22  
4.5 RATIONALE FOR PHARMACOKIN ETIC SAMPLING SCHEDULE ............ 22  
4.6 RATIONALE FOR WHOLE GE NOME SEQUENCING ................................... 23  
5 SUBJECT SELECTION ................................................................................................... 23  
5.1 SCREENING PROCEDURES ............................................................................. 23  
5.2 CHECK-IN PROCEDURES ................................................................................ 23  
5.3 INCLUSION CRITERIA ...................................................................................... 24  
5.4 EXCLUSION CRITERIA .................................................................................... 25  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 5 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 5.5 REMOVAL OF SUBJECTS FROM STUDY PARTICIPATION  ....................... 27  
6 ASSESSMENT OF SAFETY  ........................................................................................... 28  
6.1 SAFETY PLAN  .................................................................................................... 28  
6.1.1  RISKS ASSOCIATED WITH GDC -0134 ......................................... 28  
6.1.2  CONTRAINDICATIONS WITH GDC-0134 .................................... 28  
6.1.3  SERIOUS ADVERSE DRUG REACTIONS  ..................................... 28  
6.1.4  POTENTIAL RISKS  .......................................................................... 29  
7 STUDY PROCEDURES  .................................................................................................. 32  
7.1 SCHEDULE OF STUDY ACTIVITIES  .............................................................. 32  
7.2 STUDY TREATMENT  ........................................................................................ 39  
7.2.1  DRUG SUPPLIES AND ACCOUNTABILITY  ................................ 39  
7.2.2  DOSE PREPARATION AND ADMINISTRATION  ........................ 41  
7.3 REMOVAL OF STUDY BLIND  ......................................................................... 41  
7.4 DIET, FLUID, AND ACTIVITY CONTROL  ..................................................... 42  
7.5 CONCOMITANT MEDICATIONS  .................................................................... 42  
7.6 PHARMACOKINETIC BLOOD AND URINE SAMPLE COLLECTION AND 
PROCESSING  ...................................................................................................... 44  
7.7 ANALYTICAL METHODOLOGY  ..................................................................... 44  
7.8 CLINICAL LABORATORY EVALUATIONS  .................................................. 44  
7.9 SAMPLES FOR THE RESEARCH BIOSAMPLE REPOSITORY  .................... 45  
7.9.1  OVERVIEW OF THE RESEARCH BIOSAMPLE REPOSITORY  . 45  
7.9.2  APPROVAL BY THE INSTITUTIONAL REVIEW BOARD  ......... 46  
7.9.3  MANDATORY SAMPLES FOR WHOLE GENOME SEQUENCING SAMPLE COLLECTION  ................................................................... 46
 
7.9.4  CONFIDENTIALITY ......................................................................... 46  
7.9.5  CONSENT TO PARTICIPATE IN THE RESEARCH BIOSAMPLE 
REPOSITORY  .................................................................................... 47  
7.9.6  WITHDRAWAL FROM THE RESEARCH BIOSAMPLE REPOSITORY  .................................................................................... 47
 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 6 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 7.9.7  MONITORING AND OVERSIGHT  ................................................. 48  
7.10  12-LEAD ELECTROCARDIOGRAMS  .............................................................. 48  
7.11  VITAL SIGNS  ...................................................................................................... 49  
7.12  HOW DO YOU FEEL? INQUIRY  ...................................................................... 49  
7.13  PHYSICAL EXAMINATIONS  ........................................................................... 49  
7.14  OPHTHALMOLOGY ASSESSMENTS .............................................................. 49  
7.15  CLINIC DISCHARGE PROCEDURES  .............................................................. 50  
7.16  STUDY COMPLETION/EARLY TERMINATION PROCEDURES  ................ 50  
8 ADVERSE EXPERIENCES  ............................................................................................ 50  
8.1 SAFETY PARAMETERS AND DEFINITIONS  ................................................ 50  
8.1.1  ADVERSE EVENTS  .......................................................................... 50  
8.1.2  SERIOUS ADVERSE EVENTS (IMMEDIATELY REPORTABLE 
TO THE SPONSOR)  .......................................................................... 51  
8.1.3  ADVERSE EVENTS OF SPECIAL INTEREST (IMMEDIATELY REPORTABLE TO THE SPONSOR)  ............................................... 52
 
8.2 METHODS AND TIMING FOR CAPTURING AND ASSESSING SAFETY PARAMETERS  .................................................................................................... 52
 
8.2.1  ADVERSE EVENT REPORTING PERIOD  ..................................... 52  
8.2.2  ELICITING ADVERSE EVENT INFORMATION  .......................... 53  
8.2.3  ASSESSMENT OF SEVERITY OF ADVERSE EVENTS  ............... 53  
8.2.4  ASSESSMENT OF CAUSALITY OF ADVERSE EVENTS ........... 54  
8.3 PROCEDURES FOR RECORDING ADVERSE EVENTS  ................................ 55  
8.3.1  RECORDING ADVERSE EVENTS ON THE CASE REPORT FORM ................................................................................................. 55
 
8.4 IMMEDIATE REPORTING REQUIREMENTS FROM PRINCIPAL INVESTIGATOR TO SPONSOR  ........................................................................ 60
 
8.4.1  REPORTING REQUIREMENTS FOR FATAL OR LIFE-
THREATENING SERIOUS ADVERSE EVENTS  ........................... 61  
8.4.2  REPORTING REQUIREMENTS FOR ALL SERIOUS ADVERSE EVENTS  ............................................................................................. 61
 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 7 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 8.4.3  REPORTING REQUIREMENTS FOR CASES OF ACCIDENTAL 
OVERDOSE OR MEDICATION ERROR  ........................................ 63  
8.4.4  FOLLOW -UP OF SUBJECTS AFTER ADVERSE EVENTS .......... 64  
8.5 ADVERSE EVENTS THAT OCCUR AFTER THE ADVERSE EVENT REPORTING PERIOD  ......................................................................................... 64
 
8.5.1  EXPEDITED REPORTING TO HEALTH AUTHORITIES, PRINCIPAL INVESTIGATORS, AND INSTITUTIONAL REVIEW BOARDS  ............................................................................................ 65
 
9 STATISTICAL ANALYSES  ........................................................................................... 65  
9.1 SAFETY AND TOLERABILITY ANALYSIS ................................................... 66  
9.2 PHARMACOKINETIC ANALYSIS  ................................................................... 66  
9.3 WHOLE GENOME SEQUENCING ANALYSIS  ............................................... 67  
9.4 INTERIM ANALYSIS  ......................................................................................... 67  
9.4.1  OPTIONAL INTERIM ANALYSIS  .................................................. 68  
9.5 STATISTICAL ANALYSIS OF PHARMACOKINETIC DATA  ....................... 68  
9.6 STATISTICAL ANALYSES OF SAFETY DATA  ............................................. 68  
9.7 SAMPLE SIZE ..................................................................................................... 69  
9.8 QUALITY CONTROL AND QUALITY ASSURANCE  .................................... 69  
10 ADMINISTRATIVE ASPECTS  ...................................................................................... 69  
10.1  CHANGE IN PROTOCOL ................................................................................... 69  
10.2  PRINCIPAL INVESTIGATOR MEETING; SITE INITIATION  ....................... 69  
10.3  DISCLOSURE  ...................................................................................................... 69  
10.4  MONITORING (CLINICAL RESEARCH ASSOCIATE)  ................................. 70  
10.5  INSTITUTIONAL REVIEW BOARD ................................................................. 70  
10.6  INFORMED CONSENT  ...................................................................................... 70  
10.7  RECORDS  ............................................................................................................ 71  
10.7.1  ELECTRONIC CASE REPORT FORMS  ......................................... 71  
10.7.2  SOURCE DATA DOCUMENTATION ............................................. 72  
10.7.3  USE OF COMPUTERIZED SYSTEMS ............................................ 72  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 8 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 10.7.4  STUDY MEDICATION ACCOUNTABILITY ................................. 73  
10.7.5  DISCLOSURE OF DATA .................................................................. 73  
10.7.6  RETENTION OF RECORDS ............................................................. 74  
10.8  REFERENCE TO DECLARATION OF HELSINKI/BASIC PRINCIPLES  ...... 74  
PRINCIPAL INVESTIGATOR AGREEMENT  .......................................................................... 75  
PRINCIPAL INVESTIGATOR AGREEMENT  .......................................................................... 76  
SPONSOR AGREEMENT  ........................................................................................................... 77  
REFERENCES ............................................................................................................................. 78  
APPENDIX A – CLINICAL LABORATORY EVALUATIONS  ............................................... 79  
APPENDIX B – APPROXIMATE MAXIMUM BLOOD VOLUME COLLECTED ................ 80  
 
TABLE OF TABLES  
 
Table 7-1  Schedule of Activities – Part 1.............................................................................. 33 
Table 7-2  Schedule of Activities – Part 2.............................................................................. 36 
Table 7-3  Plasma Pharmacokinetic Sampling Scheme (All Study Periods)  ......................... 39  
Table 7-4  Study Drug ............................................................................................................ 40  
Table 8-1  Adverse Event Severity Grading Scale for Events Not Specifically Listed in WHO Toxicity Grading Scale  ............................................................................... 54
 
Table 8-2  Causal Attribution Guidance ................................................................................. 55  
 
TABLE OF FIGURES  
 
Figure 1 Study Schematic of Crossover Design – Part 1  .................................................... 21 
Figure 2 Study Schematic of Crossover Design – Part 2  .................................................... 21 
 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 9 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 ABBREVIATIONS  
Aeu amount excreted in urine over a sampling interval 
AE adverse event  
AESI adverse event of special interest  
ALS amyotrophic lateral sclerosis  
ALT alanine aminotransferase 
anti-HCV hepatitis C virus antibody  
AST aspartate aminotransferase 
AUC area under the concentration- time curve  
AUC0-t area under the concentration-time curve from Hour 0 to the last measurable 
concentration  
AUC0-∞ area under the concentration-time curve extrapolated to infinity 
BMI body mass index 
CBC complete blood count 
CFR Code of Federal Regulations 
CI confidence interval 
Cmax maximum observed concentration  
CL/F apparent systemic clearance 
CLR renal clearance 
CPET Clinical Pharmacology Protocol Execution Team 
CRU Clinical Research Unit  
Ct last measurable concentration  
Ctrough concentration at the end of a dosing interval at steady state 
DLK dual leucine zipper kinase 
ECG electrocardiogram  
EC Ethics Committee  
eCRF e lectronic Case Report Form  
EDC electronic data capture  
ERG electroretinography  
ET Early Termination  
FDA Food and Drug Administration 
%Feu percentage of dose excreted in urine over a sampling  interval 
FSH follicle-stimulating hormone 
GCP Good Clinical Practice  
GI gastrointestinal  
HBsAg hepatitis B surface antigen  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 10 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 HDYF? How do you feel?  
HIV human immunodeficiency virus 
HRT hormone replacement therapy 
IB Investigator’s Brochure 
ICF Informed Consent Form 
ICH International Conference on Harmonis ation/International Council for 
Harmonisation  
IND Investigational New Drug IOP intraocular pressure  
IRB Institutional Review Board  
JNK c-jun N- terminal kinase  
OSE open- label safety expansion  
PD pharmacodynamic (s) 
PI Principal Investigator  
PK pharmacokinetic (s) 
PPD purified protein derivative 
PPI proton pump inhibitor 
PPS peripapillary swelling  
QD once daily  
QTcF QT interval corrected through use of Fridericia’s formula  
RBC red blood cell 
RBR R esearch Biosample Repository 
RNFL retinal nerve fiber layer  
SAE serious adverse event  
SAP Statistical Analysis Plan  
TB tuberculosis 
TEM transmission electron microscopy  
t
1/2 apparent terminal elimination half -life 
tmax time to maximum observed concentration 
UA urinalysis  
ULN upper limit of normal 
Vz/F apparent volume of distribution during the terminal phase 
WBC white blood cell  
WGS whole genome sequencing 
λz apparent terminal elimination rate constant  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 11 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 1 SYNOPSIS  
Title of Study:  A Phase I Study to Determine  the Relative Bioavailability of Various Formulations  
GDC-0134 in Healthy Female Subjects o f Non-Childbearing  Potential 
Objectives:  The primary objectives of this study are:  
• To determine the relative bioavailability of GDC-0134 F16 capsule s (newly 
developed capsule formulation with GDC -0134 malate drug substance ) with 
respect to the current clinical material,  GDC-0134 F09 capsules, with a standard 
meal. 
• To determine the relative bio availability of GDC-0134 F15 capsule s (newly 
developed capsule formulation with GDC -0134 freebase)  with respect to the 
current clinical material , GDC-0134 F09 capsules, under fasted conditions.  
A description of test products is provided below.  
 
The secondary objectives of this study are:  
• To determine the safety and tolerability of a single oral dose of GDC-0134 in 
healthy subjects.  
• To characterize the pharmacokinetic s (PK) of GDC-0134 after oral 
administration in healthy subjects.  
 
The exploratory objective  of this study is: 
• To determine the urinary elimination of GDC- 0134 
Methodology/Study 
Design: This will be an open -label, randomized, 2 -period crossover study consisting of two parts 
to determine:  
• Part 1 – the relative bioav ailability of GDC -0134 F16 capsule s (Ro 704-
0814/F16) and GDC -0134 F09 capsules (Ro 704-0814/F09)  with a standard 
meal 
• Part 2 – the relative bioavailability of GDC -0134 F15 capsule s (Ro 704-
0814/F15) and  GDC-0134 F09 capsules (Ro 704-0814/F09)  under fasted 
conditions  
In each part of the study,  plasma PK samples will be collected through  21 days postdose 
and urine samples will be co llected through 48 hours postdose .  The following safety 
assessments will be conducted  at specific times during the study: physical examination, 
12-lead electrocardiogram  (EGC), vital signs, “How do you feel” inquiries (to assess 
adverse events [ AEs]), ophthalmology, and clinical laboratory evaluations.  
Number and General 
Description of Subjects:  Twenty-two healthy female subjects of non -childbearing potential  will be enrolled in  
each part of the study,  in order for at least 18 subjects (9 per  treatment sequence) to 
complete each part (Part 1 and Part 2).  If the two parts of the study are run sequentially, 
subjects will be encouraged to  participate in  both parts.  The maximum number of 
subjects enrolled into the study will be  approximately  44. 
Diagnosis and Main 
Criteria for Inclusion:  Female subjects of non -childbearing potential between 18 and 65 years of age, inclusive, 
and within body mass index range of 18.5 to 35 kg/m2, inclusive .  
Test Product(s), Dose, 
and Mode of Administration:  Study Drug Product  Description  Study 
Designation  
GDC-0134 F09 capsule, 
200 mg (aka  GDC-0134 
capsules, 200 mg in 
Investigational New Drug  
CMC dossier)   Reference drug, current clinical 
material GDC-0134 F09  
capsule 
GDC-0134 F15 capsule, 
200 mg Test drug, newly developed 
capsule formulation with GDC -
0134 freebase  GDC-0134 F15 
capsule 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 12 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 GDC-0134 F16 capsule, 
200 mg Test drug, newly develop ed 
capsule formulation with 
GDC-0134 malate drug 
substance  GDC-0134 F16 
capsule 
Subjects will receive the following treatments, according to a randomization schedule 
generated by a Covance biostatistician:  
Part 1: 
• GDC-0134 F16 capsule s (Ro 704-0814/F16) - 800 mg, oral, with a standard 
meal 
• GDC-0134 F09 capsules (Ro 704-0814/F09)  - 800 mg, oral , with a standard 
meal 
Part 2: 
• GDC-0134 F15 capsule s (Ro 704-0814/F15) - 800 mg, oral , fasted 
• GDC-0134 F09 capsules (Ro 704-0814/F09) - 800 mg, oral , fasted 
Duration of Treatment:  Planned Enrollment/Screening Duration :  approximately 4 weeks 
Length of Each Confinement :  approximately 1 day predose until approximately 2 days 
postdose. 
Planned Individual Study Part Duration:  approximately 11 weeks 
Criteria for Evaluation :  
Safety Safety assessments will include clinical laboratory evaluations, physical examinations, 
ECGs, ophthalmology, and vital signs.  In addition, the nature, frequency and severity of 
treatment -emergent AEs  will be collected and summarized.  
Criteria for Evalua tion:  
Pharmacokinetics  The following PK parameters will be derived from the plasma concentrations of GDC-
0134 using the model independent approach: Maximum observed concentration (C max), 
time to maximum observed concentration (t max), area under the concentration -time curve 
(AUC) from Hour 0 to the last measurable concentration (AUC 0-t), AUC extrapolated to 
infinity (AUC 0-∞), apparent terminal elimination rate constant ( λz), terminal elimination 
half-life (t1/2), apparent systemic clearance (CL/F),  and apparent volume of distribution 
during the terminal phase (V z/F). 
The following PK parameters will be derived from the urine concentrations of 
GDC-0134: amount excreted in urine over a sampling interval (A eu), cumulative amount 
excreted in urine (Total A eu), percentage of dose excreted in urine over a sampling 
interval (%F eu), cumulative percentage of dose excreted in urine (Total %F eu), and renal 
clearance (CL R). 
Statistical Methods:  The primary parameters for analysis will be AUC0-∞, and C max of GDC-0134. A linear  
mixed model will be applied to analyze the log -transformed primary PK parameters. The 
model assumes fixed effects for formulation, period, and sequence, and a random effect 
for subject within  sequence. Estimates of geometric mean rat ios on the original scale, 
together with the corresponding 90% CIs, will be derived for the comparisons between 
Test and Reference treatments.   
Descriptive statistics will be calculated on the PK data. No formal statistical  analyses are 
planned for safety data. 
 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 13 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 2 INTRODUCTION  
2.1 BACKGROUND  
GDC-0134 (also known as G02792134 and RO7040814) is a pote nt, selective, orally available  
and brain- penetrant small  molecule inhibitor of dual leucine zipper kinase (DLK) being 
developed as a therapeutic for amyotrophic lateral sclerosis (ALS).  Dual leucine zipper kinase 
has been identified as a central regulator of neuronal degeneration in a variety of settings, and 
regulates pathways active in chronic neurodegenerative diseases.  Both in vitro and no nclinical in 
vivo studies support the hypothesis that GDC -0134-mediated inhibition of D LK may benefit 
patients with  both familial and sporadic ALS. 
 ALS is a devastating, incurable neurodegenerative disease of upper and lower motor neurons that 
affects appr oximately three  in every 100,000 adults in the United States, most commonly people 
between the ages of 40 and 70 years ( 1).  Degeneration of motor neurons leads to loss of motor 
control and strength (which affects the limbs, speech, swallowing, and respiration) , resulting in  
the need for permanent respiratory support and ultimately death.  Although significant heterogeneity does exist in the rate of disease progression, the majority of patients with ALS die within 3 to 5 years after disease diagnosis ( 1). 
 The mechanisms of motor neuron loss ar e currently unknown and a common pathophysiological 
mechanism has yet to be identified.  Despite numerous clinical trials exploring multiple interventions ( 2), there have been limited  successes, with r iluzole and edaravone being the only 
medications approved in the U nited States for treatment of ALS.   Riluzole , a tetrodotoxin-
sensitive sodium channel antagonist confers only a modest (2 -3 months)  survival benefit and has 
not consistently demonstrated functional benefit ( 3).  Edaravone, a free radical scavenger, was 
approved for the treatment of ALS in 2017 in the United S tates and in Canada in 2018. A 
survival benefit has not been established (Radicava® U.S. Package Insert).  While this recent 
approval brings one more treatment option to ALS patients, there remains a high unmet medical need for novel therapeutic approaches that could improve function and prolong survival.  Dual leucine zipper kinase is  a member of the mixed- lineage kinase family that is an upstream 
regulator of the c-jun N- terminal kinase ( JNK) pathway. This pathway has been shown to 
contribute to axon degeneration and neuronal apoptosis following nerve injury and excitotoxic insult and in models of chronic neurodegenerative disease ( 4-6).  Motor neurons in particular 
appear to require DLK in order to degenerate, and loss of DLK signaling is potently 
neuroprotective in this cell type ( 4, 8).  Stress -induced activation of the DLK/ JNK pathway is 
evident in motor neurons of a mouse model of ALS, and genetic reduction  of DLK protects 
Clinical Protocol 
Covance Study 8398091 CONFIDENTIAL 
Protocol GP40957 
 
 
Final:  19 December 2018 Page 14 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 motor neurons from degeneration, preserves moto r function, and extends survival in the SOD1 
G93A mouse ( 9).   
 
Expression of DLK is limited largely to neurons of the central and peripheral nervous systems 
(7), and does not have an impact on normal physiological JNK activity (4, 5).  Inhibition of DLK 
by GDC-0134, therefore, provides a highly specific approach to  preventing neurodegeneration.  
2.2 OVERVIEW OF GDC-0134 CL INICAL DEVELOPMENT 
There have been two recent clinical studi es evaluating GDC-0134.  A randomized, double-blind 
Phase I study (Study GN29823) is ongoing in pati ents with ALS to evaluate the safety, 
tolerability and pharmacokinetics (PK) of GDC-0134.  An open-label, cross over clinical pharmacology study (Study GP39778) is complete d and was conducted in healthy female 
subjects of non-childbearing potential to inves tigate the relative bi oavailability of two 
formulations of GDC-0134 and to evaluate the effect of food, a proton pump inhibitor (PPI), and applesauce preparation on GDC-01 34 absorption and disposition. 
 As of 22 October 2018, Study GN29823 has enrolled 43 male and female patients with ALS who 
have received GDC-0134 or placeb o.  GDC-0134 has had a favorable  safety profile in all single 
dose, multiple-dose, and open-label safety expansion (OSE) cohorts evaluated in Study GN29823.  There have been no reported deaths; one serious adverse event (SAE) in the OSE 
stage at 400 mg once daily (QD) (life-threaten ing thrombocytopenia confounded by concomitant 
medications including cephalexin and ibuprofen ), one dose-limiting AE (DLAE) in multiple 
ascending dose (MAD) stage at 800 mg (non-serious AE of blurred vision with no objective 
findings), and four withdrawals due to AEs have been observed (two in the single ascending dose 
[SAD] stage [one asymptomatic non-serious increa se in intraocular pre ssure (IOP); and one non-
serious asymptomatic increase in  blood bilirubin 161 days after last dose], one in the MAD [the 
DLAE described previously] and one in the OSE [the SAE described previously]) (see the Investigator Brochure [IB] for full details [ 10]). 
 In the completed Study GP39778, a total of 18 healthy female subjects each have received four 
single doses (200 mg each) of GDC-0134, separated by approximately 3 weeks.  Overall, single doses of GDC-0134 were well tolerated.  There were no deaths, no SAEs, and no withdrawals 
due to AEs.  There was one severe AE of asym ptomatic increased transaminases approximately 
2 days after dosing with formul ated GDC-0134 with high-fat meal in combination with 20 mg 
rabeprazole following prior administration of rabe prazole for 3 days (see the IB for full details 
[10]).  
 
Clinical Protocol 
Covance Study 8398091 CONFIDENTIAL 
Protocol GP40957 
 
 
Final:  19 December 2018 Page 15 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 2.3 CLINICAL PHARMACOKINETICS OF GDC-0134 
The clinical pharmacokinetics of GDC-0134 has b een investigated in ongoing and completed 
clinical studies.  As of 15 September 2018, preliminary PK data from Study GN29823 are 
available from 17 patients receiving escalati ng single oral doses of GDC-0134 and from 
24 patients administered 100- 1200 mg GDC-0134 QD for a planned treatment period of 28 
consecutive days in the MAD stage.  The PK  data from completed Study GP39778 are available 
from 18 healthy volunteers who received  200 mg single oral doses of GDC-0134.  
In Study GN29823, following a single dose, GDC-0134 was rapidly absorbed with peak 
concentrations achieved at around 1.5 hours (media n time to maximum observed concentration 
[tmax]) after dosing.  Biphasic elimination with a relatively rapid decline in drug concentration 
was observed right after t max of up to 6− 12 hours, followed by a slower decline of up to 
168 hours.  Mean apparent term inal elimination half-life (t 1/2) of GDC-0134 following a single 
dose was approximately 89 hours.  GDC-0134 exposure in the fasted state in creased with dose in 
an approximately dose-proportional manner across the dose range tested to date (20-640 mg). 
 Following multiple doses (100-1200 mg QD) of GDC-0134 in the MAD stage of Study GN29823, plasma concentrations of GDC-0134 incr eased with dose after a single dose and at 
steady state in MAD (100-1200 mg); however, the increase was less than dose proportional 
within the MAD dose range tested.  Consistent with the long terminal elimination half-life, 
median accumulation following QD dosing was approxi mately 2 to 3-fold relative to single dose 
C
max and area under the concentration-time curve from 0 to 6 hours (AUC 0-6). 
 In Study GP39778, following analysis of the plasma  concentrations of GDC-0134 to determine 
the effect of formulation, food, and PPI use in healthy volunteers, no si gnificant difference in 
GDC-0134 exposures between powder-in-capsule a nd formulated capsule were observed at 
200 mg.  Statistically significant increases in systemic exposure (C
max and AUC) to GDC-0134 
were observed with a high-fat meal (1.1 to  1.4 fold) or applesauce preparation (1.4 − 2.8 fold) 
compared to fasted condition.  Systemic exposure (C max and AUC) to GDC-0134 significantly 
decreased (26%-60% of c ontrol) in the presence of  a PPI, rabeprazole (administered to subjects 
after an overnight fast).  However, this effect was partially attenuated by the consumption of a 
high-fat meal (46%− 99% of control). In addition, a reduction in inter-sub ject exposure variability 
was observed when GDC-0134 was administered with a high-fat meal, as an applesauce 
preparation, or with a PPI compared with when it  was administered alone in the fasted condition. 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 16 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 2.4 STUDY RATIONALE  
GDC-0134 is a novel molecule being developed by Genentech as a therapeutic for the treatment 
of patients with ALS.  GDC-0134 is intended for oral administration, and the current formulation of the drug has been investigated in its free base form.  
 In this study, the systemic exposure to GDC-0134 following oral administration of the current GDC-0134 formulation (GDC-0134 F09 capsule, Ro 704-0814/F09) and the newly developed capsule formulation with GDC-0134 malate drug substance (GDC-0134 F16 capsule) will be investigated to determine the relative bioavailability.  A newly developed capsule formulation with GDC-0134 free base (GDC-0134 F15 capsules) will also be compared against the current clinical material GDC -0134 F09  capsules.  
2.5 DOSE RATIONALE  
A maximum of 800 mg single dose is  proposed for this study; this dose is considered safe based 
on clinical safety data. In the ongoing P hase I GN29823 study in patients with ALS, single doses 
of 20 mg through 640 mg and multiple doses of 100 mg through 1200 mg QD have been well 
tolerated to date  (see Section 2.2). 
 The highest dose tested in the Phase I study , 1200 mg QD dose, is  expected to provide an 
exposure margin  of >5-fold compared to 800 mg single dose of the current clinical material, 
GDC-0134 F09 capsules, in fasted condition (1200 mg once daily dosing in patients with ALS resulted in a steady state C
max and AUC 0-6 of 13.6 µM  and 60.1 µM*hr, respectively compared to 
a single dose of 800 mg which resulted in a C max and AUC 0-6 of 2.62 µM  and 8.58 µM*hr, 
respectively).  The PK of single doses of GDC-0134 (200 mg) were shown to be comparable between healthy volunteers (study GP39778) and patients with ALS (study GN29823).  In this study, the exposures with the GDC-0134 F16 and F15 are expected to be comparable with 
that of the current clinical material GDC-0134 F09 capsules.  Systemic exposure to  GDC-0134 
administered  with a meal is expected to be within 2-fold of the systemic exposure observed with 
current clinical material GDC -0134 F09 capsules in fasted condition.  This is based on the food 
effect observed in study GP39778 (1.1-1.4 fold; see Section  2.3), taking into account that the 
standard meal planned in this study is expected to have less of an effect than the high- fat meal in 
study GP39778.  Doses between 600 mg per day and 1200 mg per day, administered QD or divided into two 
doses, are predicted to be clinically efficacious based on the preclinical PK/PD model and the 
Clinical Protocol 
Covance Study 8398091 CONFIDENTIAL 
Protocol GP40957 
 
 
Final:  19 December 2018 Page 17 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 population PK model. Therefore,  an 800 mg single dose of GDC-0134 is proposed to understand 
the effects of formulation and food at a clinically meaningful dose. 
3 STUDY OBJECTIVES AND CO RRESPONDING ENDPOINTS 
3.1 PRIMARY OBJECTIVE 
The primary objectives of this study are: 
• To determine the relative bioavaila bility of GDC-0134 F16 capsules 
(newly developed capsule formul ation with GDC-0134 malate drug 
substance) with respect to the cu rrent clinical material, GDC-0134 F09 
capsules, with a standard meal. 
• To determine the relative bioavaila bility of GDC-0134 F15 capsules 
(newly developed capsule formula tion with GDC-0134 freebase) with 
respect to the current clinical material, GDC-0134 F09 capsules, under 
fasted conditions. 
 
A full description of stud y products is provided in Table 7-4 . 
3.2 SECONDARY OBJECTIVES 
The secondary objectives of this study are: 
• To determine the safety and tolerability of  a single oral dose of GDC-0134 in healthy 
subjects. 
• To characterize the PK of GDC-0134 after or al administration in healthy subjects. 
3.3 EXPLORATORY OBJECTIVES 
The exploratory objective of this study is: 
• To determine urinary elimination of GDC-0134 
 
3.4 ENDPOINTS 
3.4.1 PHARMACOKINETIC ENDPOINTS 
The primary PK endpoints of this study are:  
• maximum observed concentration (C max); 
• AUC extrapolated to infinity (AUC 0-∞). 
 
The secondary PK endpoints of this study are: 
Clinical Protocol 
Covance Study 8398091 CONFIDENTIAL 
Protocol GP40957 
 
 
Final:  19 December 2018 Page 18 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 • time to maximum observed concentration (t max); 
• AUC from Hour 0 to the last measurable concentration (AUC 0-t); 
• apparent terminal elimination rate constant ( λZ); 
• apparent terminal elimination half-life (t 1/2); 
• apparent systemic clearance (CL/F); 
• apparent volume of distributi on during the terminal phase (V z/F). 
 
The exploratory PK endpoint s of this study are:  
• amount excreted in urine over a sampling interval (A eu); 
• cumulative amount excreted in urine (Total A eu); 
• percentage of dose excreted in ur ine over a sampling interval (%F eu); 
• cumulative percentage of dose excreted in urine (Total %F eu); 
• renal clearance (CL R). 
 
3.4.2 SAFETY ENDPOINTS 
The Safety endpoints of this study are: 
• Incidence, nature, and severi ty of AEs (assessed and graded  according to the grading 
criteria in Section 8.2.3 ); 
• Changes in vital signs, el ectrocardiograms (ECGs), phys ical examination findings, 
ophthalmology assessment findings, and clinical  laboratory results during and following 
GDC-0134 administration. 
4 STUDY DESIGN 
4.1 DESCRIPTION OF THE STUDY 
This will be an open-label, randomized, 2-period crossover study consis ting of two parts to 
determine:  
• Part 1 – the relative bioavaila bility of GDC-0134 F16 capsule s and the current clinical 
material, GDC-0134 F09 capsules; 
• Part 2 – the relative bioavaila bility of GDC-0134 F15 capsule s and the current clinical 
material, GDC-0134 F09 capsules. 
 
Part 1 and Part 2 may occur in parallel or consecutively in either order (Part 1 followed by Part 2, or Part 2 followed by Part 1).  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 19 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 Approximately 22 female subjects of non-childbearing potential (11 per treatment sequence) 
between 18 and 65 years of age, inclusive, will be enrolled into each p art of the study across two 
clinical research sites.  In each part, subjects will be randomized into one of two treatment 
sequences following a randomization schedule generated by Covance.  If the two parts are run 
sequentially s ubjects will be encouraged to enroll into more than one part of the study, and there 
will be a minimum of 22  days between dosing in different parts. A washout period of 21 days is 
considered to be sufficient based on the mea n terminal elimination half -life of GDC -0134 in 
patients and healthy volunteers being <100 hours, and based on a negligible residual  drug 
concentration of GDC-0134 on Day 21 in healthy volunteers ( mean C max/ concentration at the 
end of a dosing interval at steady state [C trough] ratio >300-fold).  A maximum of  approximately 
44 subjects will b e enrolled into this study. The crossover design is presented in  Figure 1 and 
Figure 2. 
 In each part of the study, potential subjects will be screened to assess their eligibility to enter the study within 2 7 days prior to Check -in (Day - 1) for their first treatment period .  Replacement 
subjects may be enrolled, only if deemed necessary by the Sponsor, to ensure that 18  subjects 
complete each part of the study (9 subjects per treatment sequence).  For all subjects, routine 
screening procedures, as outlined in Section 5.1, will be performed. 
 In both parts of the study, eligible subjects will be admitted to the Clinical Research Units (CRUs) on the day prior to dosing for each period (Check -in; Day -1) to collect baseline data and 
to familiarize the subjects with study procedures that will be used during the rest of the study.  Randomization will occur on Day 1 of Period 1.  
Part 1 
 In Part 1, Period s 1 and 2, eligible subjects will receive 800 mg of either GDC-0134 F16 
capsules or the current clinical material , GDC-0134 F09  capsules ( Ro 704-0814/F09), orally with 
a standard meal on Day 1 according to the randomization schedule.  Subjects will be confined to the CRU from  Check-in (Day -1) until Discharge on Day 3.  Subjects will be required to return 
to the CRU for outpatient visits on Days 5, 7, and 15 (or at Early Termination [ET]).  Check-in (Day -1) for Period 2 will occur 20 days after dosing in Period 1. 
 
Part 2 
In Part 2, Periods 1 and 2, subjects will receive 800 mg of GDC -0134 F15 or the current clinical 
material, GDC-0134 F09  capsules, after an overnight fast according to the randomization 
schedule on Day 1. Subjects will not receive food for 4 hours postdose.  Part 2 may occur before, after, or in parallel with Part 1.  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 20 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018  
Subjects will be confined to the CRU from Check-in (Day -1) until Discharge on Day 3 during each period .  Subjects will be required to return to the CRU for outpatient visits on Days  5, 7, 
and 15 (or at ET). Check-in (Day - 1) for Period 2 will occur 2 0 days after dosing in Period 1. 
 A detailed list of assessments is included in Table 7-1 and Table  7-2. 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 21 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 Figure 1 Study Schematic of Crossover Design – Part 1  
 
GDC -0134 F09 
capsule
GDC -0134 F16 
capsuleGDC -0134 F16 
capsule
GDC -0134 F09 
capsulePeriod 1 Period 2
Sequence A
(n = 11)
Sequence B
(n = 11)
Standard meal 
Note: F09 capsules = current clinical material of GDC- 0134; F16 capsule s = newly developed capsule formulation 
with GDC -0134 malate drug substance  
 
 
Figure 2 Study Schematic of Crossover Design – Part 2  
 
GDC -0134 F09 
capsule
GDC -0134 F15 
capsuleGDC -0134 F15 
capsule
GDC -0134 F09 
capsulePeriod 1 Period 2
Sequence A
(n = 11)
Sequence B
(n = 11)
Fasted 
Note: F09 capsules = current clinical material of GDC- 0134; F15 capsule s = newly developed capsule formulation 
with GDC -0134 free  base 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 22 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 In this study design, physical examinations, 12- lead ECGs, vital signs, “ How do you feel?” 
(HDYF?) inquiries,  ophthalmology assessments, and clinical laboratory evaluations 
(Appendix A ) will be performed at Screening, at specified times during the study, and/or at 
Study Completion (for specific timepoints and details on each study variable, refer to Section 7).  
After informed consent has been obtained but prior to initiation of study drug administration 
(Day 1), only SAEs  caused by protocol-mandated interventions will be reported.  After initiation 
of study drug administration on Day 1 of each study part, all AEs, whether volunteered, elicited, 
or noted upon physical examination, will be recorded throughout the study until 28 days after the 
last dose of the study (i.e., from Day 1 until St udy Completion/ET).   Following administration of 
each treatment in each study part, plasma PK samples will be collected through 21 days postdose 
and urine PK samples will be collected through 48 hours postdose.   A Schedule of A ctivities is 
presented in  Table 7-1 and Table 7-2. 
4.2 RATIONALE FOR STUDY DESIGN 
This study will assess the relative bioavailability of newly developed formulations of GDC-0134 compared to the current clinical material in healthy females of non -childbearing potential.   A 
single dose, randomized, 2 part, 2-period crossover study design was considered acceptable to achieve the study objectives.  This study will not be blinded as the primary endpoints (GDC-0134 PK) are not subjective or able to be biased by knowledge of study sequence. 
4.3 RATIONALE FOR SUBJECT POPULATION 
The study will exclude women of childbearing potential and will be limited to healthy female 
subjects of non-childbearing potential based on findings of maternal toxicity and significant fetal malformations in nonclinical studies in pregnant rats and rabbits (see Section 2.1 and the IB  [10] 
for further details).  Males are excluded based on findings of testicular toxicity observed in male 
rats (see Sections 6.1.4.10).  Clinical experience in humans is still limited to assess the 
translatability of these nonclinical findings to humans. 
4.4 RATIONALE FOR EXPLORATORY ASSESSMENTS  
Urine samples will be collected to determine urinary elimination of GDC -0134. 
4.5 RATIONALE FOR PHARMACOKINETIC SAMPLING SCHEDULE  
The frequent sampling schedule is designed to capture data at a sufficient number of timepoints 
to provide a detailed profile of the concentration-time curve, including maximum observed 
concentration (C
max), time to maximum observed concentration (t max), and apparent terminal 
elimination  half-life (t1/2). 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 23 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 4.6 RATIONALE FOR WHOLE GENOME SEQUENCING  
A whole blood sample will be collected from all subjects for DNA extraction to enable whole 
genome sequencing (WGS). Genomics is increasingly informing researcher’s understanding of disease pathobiology.  Whole genome sequencing pr ovides a comprehensive characterization of 
the genome and, through the generation of control data from healthy subjects along with clinical data collected in this study, may increase our understanding of PK, response, human diseases, 
and the opportunity for developing new therapeutic approaches.  Data will be analyzed in the context of this study but will also be explored in aggregate with data from other studies. The availability of a larger dataset will assist in identification of important pathways, guid ing the 
development of new targeted agents.   Given the complexity and exploratory nature of these 
analyses, WGS data and analyses will not be shared with the Principal Investigators (PIs) or 
study subjects unless required by law. 
5 SUBJECT SELECTION 
Twenty-two healthy volunteer female subjects of non-childbearing potential who meet all the 
protocol inclusion criteria and none of the exclusion criteria w ill be enrolled into  each part of  the 
study.  If the two parts of the study are run sequentially, subjects will be encouraged to 
participate in multiple parts of the study as long as they continue to meet the eligibility criteria.  
If the parts are conducted sequentially, any subjects discontinued may  be replaced with new 
subjects prior to the start of each part.  The maximum possible number of subjects enrolled into 
the study will be approximately 44. 
5.1 SCREENING PROCEDURES  
Refer to Table 7-1 and Table  7-2 for procedures performed for all potential subjects at the 
Screening visit . 
 
If subjects are participating in multiple parts of the study, they will not be required to re -screen 
for the second part of the study as long as there are ≤28 days between Clinic Discharge in the 
first part and Check -in for the second part of the study. 
5.2 CHECK -IN PROCEDURES  
Refer to Table 7-1 and Table  7-2 for procedures performed a t Check-in for Periods 1 and 2 when 
subjects will report to the study site.  
 For subjects to continue their participation  in the study, the drug screen and pregnancy test must 
be negative and the clinical laboratory evaluations must be within the normal laboratory range 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 24 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 (unless deemed not clinically significant by the PIs).  In addition, continued compliance with 
concomitant medication and other restrictions will be verified.  
5.3 INCLUSION CRITERIA 
Subjects who meet the following criteria may be included in the study: 
1. Females, between 18 and 65 years of age, inclusive; 
    within body mass index ( BMI) range 18.5 to 35 kg/m2, inclusive; 
2. In good health, determined by no clinica lly significant findings from medical 
history, physical examination, 12-lead ECG, and vital signs; 
3. Clinical laboratory evaluations (including chemistry panel [fasted at least 8 
hours], complete blood count [ CBC], and urinalysis [ UA] with complete 
microscop ic analysis  (if indicated) within the reference range for the test 
laboratory, unless deemed not clinically significant by the PIs  [Gilberts syndrome 
is acceptable]) ; 
4. A normal ophthalmology assessment; m inor abnormalities or age- related changes 
are acceptable, if not considered clinically significant, as per  the judgment of the 
ophthalmologist; 
5. Negative test for selected drugs of abuse at Screening (does not include alcohol) 
and at Check-in for each study period (does include alcohol; Appendix A ); 
6. Negative for cannabinoids (tetrahydrocannabinol) at Screening and at Check -in 
for both study periods ( Appendix A ); 
7. Negative hepatitis panel ( hepatitis B virus core antibody, hepatitis B surface 
antigen [HBsAg] and hepatitis C virus antibody [anti- HCV]) and negative HIV 
antibody screens ( Appendix A ); 
8. Females of non-childbearing potential only, defined as: 
- females who are permanently sterile via hysterectomy, bilateral 
salpingectomy, and/or bilateral oophorectomy by reported medical history and/or medical records. Surgical sterilization to have occurred a minimum of 6 weeks prior to Screening  
- Females of at least 45 years of age with amenorrhea for 12 months without an 
alternative medical reason with confirmatory follicle -stimulating hormone 
(FSH) levels of ≥40 mIU/mL. The amenorrhea should not be induced by a medical condition such as anorexia nervosa, hypothyroid disease or polycystic ovarian disease, or by extreme exercise. It should not be due to concomitant medications that may have induced the amenorrhea such as oral 
contraceptives, hormones, gonadotropin-releasing hormones, anti-estrogens, 
or selective estrogen receptor modulators. Women aged > 60 years old whose 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 25 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 FSH values are not ≥40 mIU/L may be included at the discretion of the PIs  
and in consultation with the Sponsor  
9. Negative screening test for latent mycobacterium tuberculosis ( TB) infection by 
QuantiFERON® TB Gold ( Appendix A ). Indeterminate results may be confirmed 
By repeat or by a purified protein derivat ive (PPD) skin t est; 
10. Receive an explanation of the mandatory WGS  component of the study; 
11. Able to comprehend and willing to sign a n Informed Consent Form (ICF). 
5.4 EXCLUSION CRITERIA  
The following will exclude potential subjects from the study: 
1. Significant history or clinical manifestation of any metabolic, allergic, 
dermatological, hepatic, renal, hematological, pulmonary, cardiovascular (including left ventricular hypertension) , gastrointestinal  (GI), neurological, 
ophthalmologic, or psychiatric disorder, as determined by the PI  (or designee); 
2. History of significant hypersensitivity, intolerance, or allergy to any drug 
compound, food, or other substance, unless approved by the PI  (or designee); 
3. History of stomach or intestinal surgery or resection  (including cholecystectomy) 
that would potentially alter absorption and/or excretion of orally administered drugs exce pt that appendectomy  and hernia repair  will be allowed ; 
4. History or presence of an abnormal ECG at Screening or Check -in (Day -1) for 
Period 1, which  in the PIs opinion, is clinically significant (QTc interval >470 
msec, PR interval >210 msec, o r QRS complex >120 msec; abnormal ECG 
findings will be confirmed by calculating the mean of the original value and 2 repeats);   
5. History of alcoholism or drug addiction within 1 year prior to Check- in (Day -1) 
for their first treatment period ; 
6. Participation in any other investigational study drug trial in which receipt of an 
investigational study drug occurred within five  half-lives (if known) or 30 days 
(small molecule) or 90  days (biologic) for Check-in (Day - 1) of their first 
treatment period , whichever is longer;   
7. Use of any prescription medications/products within 14 days prior to Check-in 
(Day -1) for their first treatment period  and during the entire study duration, 
unless deemed acceptable by the PI (use of hormone replacement therapy [HRT], 
thyroid repla cement therapy, ophthalmic drops, or other ophthalmic procedures as 
part of the fundoscopic exam is acceptable);  
8. Use of oral antibiotics within 4 weeks or intravenous antibiotics within 8  weeks 
prior to the Screening evaluation and during the entire study duration; 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 26 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 9. Use of any over- the-counter, non- prescription preparations (including vitamins; 
minerals; and phytotherapeutic-, herbal-, and plant- derived preparations) within 
14 days prior to Check -in (Day -1) for their first treatment period and during the 
entire study duration, unless deemed acceptable by the PI (acetaminophen 
[paracetamol] is acceptable [see Section 7.5]) ; 
10. Use of acid reducing medications ( PPIs, H2 receptor ant agonists, etc.) within 
14 days prior to Check-in (Day -1) for their first treatment period  and during the 
entire study duration. As an alternative, antacids may be allowed at least 4 hours 
before or after dose; 
11. Use of strong inhibitors and inducers of CYP3A4/5 and UGT enzymes within 
14 days prior to Check-in (Day -1) for their first treatment period  until the Study 
Completion/ ET is prohibited, and alternate medications should be considered 
where possible; 
12. Use of any vaccines (including seasonal flu and H1N1 vaccines) within 14 days 
prior to Check-in (Day -1) for their first treatment period ; 
13. Use of tobacco- or nicotine-containing products (including, but not limited to, 
cigarettes, e- cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine 
lozenges, or nicotine gum) within 6 months prior to Check- in (Day -1) for their 
first treatment period  and during the entire study; 
14. Use of alcohol- or caffeine -containing foods or beverages within 72 hours prior to 
Check-in (Day -1) for their first treatment period  until Study Completion/ ET; 
15. Consumption of grapefruit, grapefruit-containing products, and pomegranate, pomelo, and star fruit juice/products within 7 days prior to Check -in (Day -1) for 
their first treatment period  and during the entire study duration; 
16. strenuous exercise within 48 hours prior to Check-in (Day -1) for their first 
treatment period  or during the period of confinement at the study site  (e.g., 
subjects will not begin a new exercise program or participate in any unusually 
strenuous physical exertion); 
17. Poor peripheral venous access;  
18. History of malignancy, except for appropriately treated c arcinoma in situ of the 
cervix, non- melanoma skin carcinoma, or Stage I uterine cancer;  
19. Donation of blood from 30 days prior to Screening through Study Completion, Clinic Discharge, or E T, inclusive, or of plasma from 2 weeks prior to Screening 
through Stu dy Completion, Clinic Discharge, or ET, inclusive; 
20. Receipt of blood products within 2 months prior to Check- in (Day -1) for their 
first treatment period ; 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 27 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 21. Subjects with best -corrected visual acuity worse than 20/40 in either eye, history 
of optic neuropathy, history of optic disc swelling or atrophy, and/or history of 
chronic eye disease ( e.g., glaucoma, uveitis, diabetic retinopathy);  
22. Any acute or chronic condition or any other reason that, in the opinion of the PI , 
would limit the subject’s ability to complete and/or participate in this clinical study; 
23. Any condition that would preclude participants from receiving a lumbar puncture during the study.  
Subjects participating in multiple parts of the study: 
24. Subjects that have received GDC -0134 within <28 days prior to Day 1  
25. Subjects that have an ongoing AE which, in the opinion of the PI, prohibits them 
from further participation in the study  
 
5.5 REMOVAL OF SUBJECTS FROM STUDY PARTICIPATION  
Subjects will be informed that they are free to withdraw from the study at any time and for any 
reason.  The PI may remove a subject from the study if, in the PI s opinion, it is not in the best 
interest of the subject to continue the study.  Subjects may b e discontinued due to the following:  
change in compliance with inclusion/exclusion criterion that is clinically relevant and affects subject safety, occurrence of AEs, occurrence of pregnancy, intake of non- permitted concomitant 
medication that might affe ct subject safety or study assessments/objectives, etc.  Notification of 
discontinuation will immediately be made to the Sponsor’s Study Monitor.  In case of premature discontinuation of study participation, efforts will be made to perform all final study day assessments (see Section  7.16).  The date the subject is withdrawn from the study and the reason 
for discontinuation will be recorded on the subject’s electronic Case Report Form (eCRF).  All 
dropouts will be followed until resolution of all their AEs or until the unresolved AEs are judged by the PI to have stabilized  or returned to baseline. 
 For subjects who are discontinued by the PI  or who voluntarily withdraw prematurely from the 
study, replacement subjects may be enrolled only if deemed necessary by the Sponsor.  Except 
for replacements, the subjects will be assigned a number by study site staff.  Assignment of 
numbers will be in ascending order and no numbers will be omitted.  Subject numbers will be used on all study documentation.  Replacement subjects will be assigned a subject n umber by 
adding 100 or 1000 to the number of the subject they are replacing (e.g., Subject No. 105 
replaces Subject No. 005). 
 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 28 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 The entire study may be discontinued at the discretion of the PI , Sponsor, or Sponsor’s Medical 
Monitor based on the occurrence of, but not limited to, the following: 
• AEs unknown to date with respect to their nature, severity, and duration; 
• Increased frequency, and/or severity , and/or duration of known AEs; 
• Medical or ethical reasons affecting the continued performance of the 
study; 
• Difficulties in the recruitment of subjects;* 
• Cancellation of drug development.* 
* For reasons that are not related to subject safety , the PI will discuss discontinuation of 
the entire study with the Sponsor prior to making any decisions. 
6 ASSESSMENT OF SAFETY  
6.1 SAFETY PLAN  
GDC-0134 is not approved, and clinical development is ongoing.  The safety plan for subjects in 
this study is based on clinical experience with GDC -0134 in completed and ongoing studies.  
The anticipated important safety risks for GDC-0134 are outlined below.  Please refer to the IB 
(10) for more details on nonclinical studies in rats and cynomolgus monkeys, and preliminary 
clinical data 
 Several measures will be taken to ensure the safety of subjects participating in this study.  
Eligibility criteria have been designed to exclude subjects at higher risk for toxicities.  Subjects 
will undergo safety monitoring during the study, including assessment of the nature, frequency, and severity of AEs. 
6.1.1 RISKS ASSOCIATED WITH GDC-0134 
There are no identified risks for GDC -0134. 
6.1.2 CONTRAINDICATIONS WITH GDC-0134 
There are no known contraindications for GDC -0134. 
6.1.3 SERIOUS ADVERSE DRUG REACTIONS  
No serious adverse drug reactions have been identified for GDC-0134. 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 29 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 6.1.4 POTENTIAL RISKS  
6.1.4.1 Phototoxicity  
A 3-day, multiple -dose phototoxicity study in rats showed no direct dermal effects, but ocular 
findings were observed in UVR-exposed rats and included inflammation and edema in the 
cornea and hyperplasia of the anterior lens epithelium.  These findings were considered consistent with phototoxicity.  To prevent potential phototoxicity, subjects will be advised to avoid exposure to direct sunlight with the use of protective clothing, hats, sunglasses, and repeated application of sunscreen for 19 days after  last dosing. 
6.1.4.2 Skin Lesions  
Skin lesions (erosions/ulcerations/scabs/sores/red discharge/alopecia) were observed in rats and monkeys with a dose- related effect.  The tail was the most commonly affected area in monkeys, 
requiring amputation of the tail tip in s ome animals.  Therefore, complete physical examinations, 
including a complete examination of the skin, will be conducted throughout the study to monitor for skin ulcerations or discolorations that may be indicative of study drug-induced toxicity.  Limited, symptom-directed physical examinations may also be performed.  In addition, subjects 
will be asked to do self-examinations on a daily basis. 
6.1.4.3 Hypothermia  
In repeat- dose toxicity studies in rats, mild reversible body temperature decreases of 
approximately 0.5
oC were observed.  In single- and repeat -dose toxicity studies of GDC-0134 in 
monkeys, dose-dependent decrease in oral body temperature was noted at higher doses in the 4-
week study, but was not observed in the 39-week study.  Body temperature will be monitored at baseline and during the study.  
6.1.4.4 Retinal Toxicity  
Nonclinical toxicology studies with DLK inhibitors have identified reversible peripapillary swelling (PPS) or optic disc edema by ocular examination and retinal nerve fiber layer (RNFL) 
thickening by optical coherence tomography in cynomolgus monkeys after multiple days of 
dosing that returns to near baseline after continued drug exposure in the majority of animals.  However, in two instances a moderate decrease in RNFL thickness was observed afte r the 
transient thickening, and in one instance a continued RNFL thinning was observed 8 weeks after the end of drug exposure.  The RNFL thickening was largely correlated with increased axon size.  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 30 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 In the two animals with thinning RNFL, increases in axon size were also noted by transmission 
electron microscopy (TEM) with one animal also observed to have minimally increased glial cell processes.  There was no evidence of axonal loss or degeneration by TEM.  On ophthalmic exams, no optic nerve head cupping was observed that would suggest elevated IOP as a factor for the RNFL thinning, and no GDC-0134- related effects were noted on IOP measurements, nor 
were any visual deficits detected in an animal, as assessed by electroretinography (full field and multi-focal ERGs) or visual evoked cortical potentials.  No GDC-0134- related ophthalmic 
abnormalities, IOP effects, fundus photographic observations, or effects on rod- and cone-driven retinal function, as assessed by scotopic and photopic ERGs, have been observed.  The 
functional consequences of this retinal change are unknown.  Patients with best- corrected visual 
acuity worse than 20/40 in either eye, history of optic neuropathy, history of optic disc swelling or atrophy, and/or history of chronic eye disease (e.g. glaucoma, uveitis, diabetic retinopathy) are excluded from the GDC- 0134 studies.  Potential ocular toxicities will be evaluated at baseline 
and throughout GDC-0134 studies as shown in the Schedule of Activities ( Table 7-1 and 
Table 7-2). 
6.1.4.5 Increased Intracranial Pressure  
As stated above, 4 -week and 39-week nonclinical toxicology studies have identified reversible 
bilateral PPS or optic disc edema in cynomolgus monkeys.  One potential mechanism of PPS or optic disc edema is increased intracranial pressure.  
 Any patient on active drug who experiences clinically significant optic disc edema on funduscopic examination, clinically significant functional visual change from baseline, or clinically significant RNFL thickening by SD -OCT that is deemed study drug rela ted will 
undergo a lumbar puncture to rule out increased intracranial pressure and will be prohibited from receiving further doses of study medication.  In addition, if clinical signs or symptoms (such as severe headache, dizziness, lethargy, vomiting, seizures, pulsatile tinnitus) raise the suspicion of increased intracranial pressure, a lumbar puncture will be performed.  Lumbar punctures should include measurement of opening pressure in the lateral decubitus position.  For all patients who undergo lumbar puncture, cerebrospinal fluid will be collected for analysis of glucose, protein, red blood cells ( RBCs), white blood cells 
(WBCs), and differential and potentially cryptococcal antigen and bacterial culture.  
 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 31 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 6.1.4.6 Cardiac hypertrophy  
Increased heart weights were observed in rats with a corresponding slight to moderate increase in 
thickness (hypertrophy) of the left ventricular wall and interventricular septum of the heart in a 26-week study.  In a 4-week study, increased heart weight without microscopic findings of hypertrophy were observed.  There were no changes in heart weight or findings of cardiac hypertrophy or other abnormal microscopic changes observed in the hearts of monkeys.  However, transient non- adverse increases in heart rate were observed after single doses, with no 
observed effects on other hemodynamic parameters, blood pressures, or ECG assessments.  
6.1.4.7 Gastrointestinal Ulcerations  
Gastrointestinal toxicities characterized by the presence of bloody feces or vomit and microscopic findings of gastric erosions or ulcerations were observed in the 4- week toxicity 
study in monkeys but generally resolved during the 4-week recovery period.  GI toxicity was the cause of moribundity and early euthanasia in two animals.  In the 39-week study in monkeys, no GI toxicity was observed.  Potential GI toxicities will be evaluated regularly by assessing for 
adverse effects that may indicate intolerability, such as nausea, vomiting, or diarrhea.  
6.1.4.8 Glycemic Dysregulation  
In nonclinical studies, effects on glucose regulation (rat and monkey) and brown adipose tissue 
macrovesicular vacuolation (monkey) were consistent with GDC-0134 potentially interfering with glycemic regulation.  Serum blood glucose and body temperature will be monitored.  
 
6.1.4.9 Hepat otoxicity  
Nonclinical studies with GDC-0134 showed an increase of unconjugated bilirubin (2-4x) in rats, 
in the absence of elevated liver enzymes.  No increases of unconjugated bilirubin or liver 
enzymes were observed in cynomolgus monkeys.  Patients with abnormal baseline clinical laboratory test results will be excluded from GDC -0134 study protocol(s), as will patients 
positive for anti-HCV or HBsAg . 
 Liver function tests, including aspartate aminotransferase (AST) , alanine aminotransferase 
(ALT), alkaline phosphatase, and total and fractionated bilirubin, will be monitored closely.  
Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy’s Law, must be reported to Sponsor as an AE  of special interest (AESI) within 24  hours (see Section 8.1.3). 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 32 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 6.1.4.10 Reproductive Toxicity  
Nonclinical findings showed decreased weights of male and female reproductive organs (rat and 
monkey), and vacuolation of some cells of the anterior pituitary gland in males (rats) were seen.  
Men will be excluded from this GDC -0134 study.  
 Maternal toxicity (e.g. excessive mortality, body weight loss, decreased activity) and multiple fetal malformations (e.g. malrotated hindlimbs, whole body subcutaneous edema, cleft snout, short tails, small mandible, absent tongue) were observed in nonclinical studies in rats and rabbits (see IB for further details).  Therefore , GDC-0134 should not be administered to pregnant 
women. Women of child bearing potential are excluded from t his study. 
7 STUDY PROCEDURES  
7.1 SCHEDULE OF STUDY ACTIVITIES  
 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 33 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 Table  7-1 Schedule of Activities – Part 1  
  Period 1  Cross 
over  Period 2   
Study 
Procedures  Part 1 Study  
Days  Screeninga Day Study 
Completion/ 
ET 
Day 43  Safety 
Follow -
Up 
 
Day 49  Days -28 
to -2 -1 1 2 3 5 7 15 21 22 23 24 26 28 36 
Period 1 Days  -1 1 2 3 5 7 15 21 22 - - - - -   
Period 2 Days  - - - - - - - -1 1 2 3 5 7 15 22 28 
Check -in to CRU   X       X         
Confined to the Study Site   X X X X    X X X X      
Discharge from CRU      X       X      
Outpatient Visit  X     X X X     X X X X  
Informed Consent  X                 
Demographics  X                 
Previous Medication and 
Compliance with 
Inclusion/Exclusion Criteria  X X                
Concomitant Medication    X X X X X X X X X X X X X X X 
Medical History  X X b 
               
Height, Weight, and BMI  c X X              X  
Physical Examination  d  X   X    X   X    X  
12-Lead ECG  X X       X       X  
Vital Signs  e X X X X X X X X X X X X X X X X  
Fundoscopic Examination  X                 
Visual acuity Assessments   X X X X    X X X X      
Visual Field Examination   X       X         
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 34 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018   Period 1  Cross 
over  Period 2   
Study 
Procedures  Part 1 Study  
Days  Screeninga Day Study 
Completion/ 
ET 
Day 43  Safety 
Follow -
Up 
 
Day 49  Days -28 
to -2 -1 1 2 3 5 7 15 21 22 23 24 26 28 36 
Period 1 Days  -1 1 2 3 5 7 15 21 22 - - - - -   
Period 2 Days  - - - - - - - -1 1 2 3 5 7 15 22 28 
AE Evaluations (HDYF? 
Inquiry)    X X X X X X X X X X X X X X X 
GDC -0134 Dosef 
  X       X        
PK Blood Samples  g   X X X X X X  X X X X X X X  
PK Urine Samplesh   X X X     X X X      
Chemistry Panel, CBC, and 
UA i X X       X      X X  
Coagulation profile  X X       X         
Hepatitis B, C, and HIV 
Screen i X                 
Tuberculosis Testing j X                 
Drug Screen (including 
cotinine) k X X       X         
Serum Pregnancy Test  X X              X  
FSH l X                 
Blood Sa mple for WGSm 
  X               
AE = adverse event; BMI = body mass index; CBC = complete blood count; ECG = electrocardiogram; ET = Early Termination; FSH = follicle -stimulating 
hormone; HDYF? = how do you feel?; HIV = human immunodeficiency virus; PK  = pharmacokinetic; TB = tuberculosis; UA = urinalysis; WGS = whole 
genome sequencing. 
a.In the event of a subject agreeing to participate in both parts of the study and there be ing ≤28 days betwe en Clinic Discharge for the first part that they 
participate in and Check-in for the second part that they participate in, subjects will not undergo re-screening for the second part. Inclusion/exclusion criteria 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 35 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 will be checked prior to completion of the first part. If there is > 28 days between Clinic Discharge for the first part the subject participates in and Check -in for 
the second part that they participate in, the subject will undergo re -screening and will sign a new ICF for the secon d part. 
b Interim medical history only.  
c Body weight recorded at Screening, Check -in (Day -1) for Period  1, and Study Completion, and height and BMI recorded at Screening only.  
d Routine physical examination ( Section 7.13) to occur at scheduled timepoints. Unscheduled abbreviated physical examinations may occur at the discretion of 
the PI (or designee).  
e Vital signs include :  oral temp erature, respiratory rate, and supine  blood pressure and pulse.  
f GDC-0134 F09 or F16 capsules will be administered 30 minutes after starting a standard meal according to the randomization schedule.  
g For PK blood samples collected during the study, refer to Table 7-3. The predose blood sample for Period 2 (study Day 22) will also be used as the Day 22 
sample for Period 1.  
h Urine PK samples collected during the study will include: predose (single sample voided within 1 hour prior to dosing), and pooled samples voided over the 
following time periods: 0-12 hours, 12 -24 hours, 24 -36 hours, and 36- 48 hours postdose.  
i Refer to Appendix A  for a list of evaluations.  
j QuantiFERON TB Gold test. If positive, subject will be excluded. Indeterminate results may be confirmed by repeat or by a PPD skin test. If a negative TB 
screening test has been documented within 3 months of Screening, no new test is needed.  
k Includes alcohol testing at Check -in (Day -1) for each period  only. 
l Follicle-stimulating hormone testing performed on postmenopausal females only . 
m Sample collected prior  to the GDC -0134 dose  on Day 1 of Period 1. If the subject participates in Part 1 and Part 2, a sample for WGS will only be taken during 
the first part of the study that the subject participates in.  
  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 36 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 Table  7-2 Schedule of Activities – Part 2  
  Period 1  Cross 
over  Period 2   
Study 
Procedures  Part 2 Study  
Days  Screeninga Day Study 
Completion/ 
ET 
Day 43  Safety 
Follow -
Up 
 
Day 49  Days -28 
to -2 -1 1 2 3 5 7 15 21 22 23 24 26 28 36 
Period 1 Days  -1 1 2 3 5 7 15 21 22 - - - - -   
Period 2 Days  - - - - - - - -1 1 2 3 5 7 15 22 28 
Check -in to CRU   X       X         
Confined to the Study Site   X X X X    X X X X      
Discharge from CRU      X       X      
Outpatient Visit  X     X X X     X X X X  
Informed Consent  X                 
Demographics  X                 
Previous Medication and 
Compliance with 
Inclusion/Exclusion Criteria  X X                
Concomitant Medication    X X X X X X X X X X X X X X X 
Medical History  X X b 
               
Height, Weight, and BMI  c X X              X  
Physical Examination  d  X   X    X   X    X  
12-Lead ECG  X X       X       X  
Vital Signs  e X X X X X X X X X X X X X X X X  
Fundoscopic Examination  X                 
Visual acuity Assessments   X X X X    X X X X      
Visual Field Examination   X       X         
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 37 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018   Period 1  Cross 
over  Period 2   
Study 
Procedures  Part 2 Study  
Days  Screeninga Day Study 
Completion/ 
ET 
Day 43  Safety 
Follow -
Up 
 
Day 49  Days -28 
to -2 -1 1 2 3 5 7 15 21 22 23 24 26 28 36 
Period 1 Days  -1 1 2 3 5 7 15 21 22 - - - - -   
Period 2 Days  - - - - - - - -1 1 2 3 5 7 15 22 28 
AE Evaluations (HDYF? 
Inquiry)    X X X X X X X X X X X X X X X 
GDC -0134 Dosef 
  X       X        
PK Blood Samples  g   X X X X X X  X X X X X X X  
PK Urine Samplesh   X X X     X X X      
Chemistry Panel, CBC, and 
UA i X X       X      X X  
Coagulation profile  X X       X         
Hepatitis B, C, and HIV 
Screen i X                 
Tuberculosis Testing j X                 
Drug Screen (including 
cotinine) k X X       X         
Serum Pregnancy Test  X X              X  
FSH l X                 
Blood Sa mple for WGSm 
  X               
AE = adverse event; BMI = body mass index; CBC = complete blood count; ECG = electrocardiogram; ET = Early Termination; FSH = follicle -stimulating 
hormone; HDYF? = how do you feel?; HIV = human immunodeficiency virus; PK = pharmacokinetic; PPD = purified protein derivative; TB = tuberculosis; 
UA = urinalysis ; WGS = whole genome sequencing. 
a. In the event of a subject agreeing to participate in both parts of the study and there be ing ≤28 days betwe en Clinic Discharge for the first part that they 
participate in and Check -in for the second part that they participate in, subjects will not undergo re -screening for the second part. Inclusion/exclusion criteria 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 38 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 will be checked prior to completion of the first part. If there is > 28 days between Clinic Discharge for the first part the subject participates in and Check -in for 
the second part that they participate in, the subject will undergo re -screening and will sign a new ICF for the second part.  
b Interim medical history only.  
c Body weight recorded at Screening, Check- in (Day -1) for Period  1, and Study Completion, and height and BMI recorded at Screening only.  
d Routine physical examination ( Section 7.13) to occur at scheduled timepoints. Unscheduled abbreviated physical examinations may occur at the discretion of 
the PI (or designee) . 
e Vital signs include:  oral temperature, respiratory rate, and supine blood pressure and pulse.  
f GDC-0134 F09 or F15 capsules will be administered  after an overnight fast  according to the randomization schedule. 
g For PK blood samples collected during the study, refer to Table 7-3. The predose blood sample for Period 2 (study Day 22) will also be used as the Day 22 
sample for Period 1. 
h Urine PK samples collected during the study will include: predose (single sample voided within 1 hour prior to dosing), and pooled samples voided over the 
following time periods: 0-12 hours, 12 -24 hours, 24 -36 hours, and 36- 48 hours postdose.  
i Refer to Appendix A  for a list of evaluations.  
j QuantiFERON TB Gold test. If positive, subject will be excluded. Indeterminate results may be confirmed by repeat or by a PPD skin test. If a negative TB 
screening test has been documented within 3 months of Screening, no new test is needed.  
k Includes alcohol testing at Check -in (Day -1) for both periods only. 
l Follicle-stimulating hormone testing performed on postmenopausal females only.  
m Sample collected prior  to the GDC -0134 dose  on Day 1 of Period 1. If the subject participates in Part 1 and Part 2, a sample for WGS will only be taken during 
the first part of the study that the subject participates in.   
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 39 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 Table  7-3 Plasma Pharmacokinetic Sampling Scheme  (All Study Periods)  
Period  
Day PK Sampling Tim epoints (Hours  Postdose) 
Window (+/ -) Analyte  (Matrix ) 
Day 1 Predose (0 Hour) any time prior to study drug 
administration  NA GDC-0134 ( Plasma) 
0.5 3 minutes  GDC-0134 ( Plasma) 
1 5 minutes  GDC-0134 ( Plasma) 
1.5 5 minutes  GDC-0134 ( Plasma) 
2 10 minutes  GDC-0134 ( Plasma) 
3 10 minutes  GDC-0134 ( Plasma) 
4 10 minutes  GDC-0134 ( Plasma) 
6 10 minutes  GDC-0134 ( Plasma) 
8 10 minutes  GDC-0134 ( Plasma) 
12 10 minutes  GDC-0134 ( Plasma) 
Day 2 24 10 minutes  GDC-0134 ( Plasma) 
Day 3 48 30 minutes  GDC-0134 ( Plasma) 
Day 5 96 6 hours GDC-0134 ( Plasma) 
Day 7 144 6 hours GDC-0134 ( Plasma) 
Day 15 336 6 hours GDC-0134 ( Plasma) 
Day 22 1 504 6 hours GDC-0134 ( Plasma) 
NA = not applicable; PK  = pharmacokinetic.  
1. The predose sample in the second period in each part (Period 2) will be used as the Day 22 PK sample for the 
first period in each part (Period 1 ).  
7.2 STUDY TREATMENT  
The Investigational Medicinal Product for this study is GDC-0134. For details on the drug 
products used in the study, refer to related Investigational New Drug ( IND) quality information 
amendment.  
7.2.1 DRUG SUPPLIES AND ACCOUNTABILITY 
The Sponsor or designee will provide the PI  with adequate quantities of the study drug (see  
Table 7-4). 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 40 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 Table  7-4 Study Drug  
Study Drug  GDC-0134 hemimalate  GDC-0134 GDC-0134 
Study Designation  GDC-0134 F16 capsule  GDC-0134 F15 capsule  GDC-0134 F09 capsule 
Description  Test drug, newly 
developed capsule 
formulation with 
GDC-0134 malate drug 
substance  Test drug, newly 
developed capsule 
formulation with 
GDC-0134 freebase  Reference drug, current 
clinical material  
Formulation  a GDC-0134 Capsule, 
200 mg (freebase 
equivalent), Ro 704-
0814/F16  form GDC-0134 Capsule, 
200 mg, Ro 704- 0814/F15  GDC-0134 Capsule, 
200 mg, Ro 704-0814/F09 
Strength  200 mg 200 mg 200 mg 
Manufacturer  Shanghai STA  
Pharmaceutical Product 
Co. Ltd Roche Basel  Patheon Inc.  
a Specific ingredients/purity will be identified on the Certificate of Analysis (or equivalent) that is supplied with the 
study drug(s).  
 
The lot numbers for the study drug will be provided to the study site by the supplier/manufacturer as soon as available.  
 Study drug will be stored at temperatures below 25
oC.  The study drug will be transferred from 
the bulk supplies into the subject’s dose container by qualified study site employees.  Each unit dose container will be appropriately labeled.  The PI or designee will maintain an accurate record of the receipt of the test materials as shipped 
by the Sponsor or designee, including the date received.  One copy of this receipt will be returned to the Sponsor when the contents of the test material shipment have been verified. In addition, an accurate drug disposition record will be kept, specifying the amount dispensed to each subject and the date of dispensation.  This drug accountability record will be available for inspection at any time.  At the completion of the study, the original drug accountability record will be available for review by the Sponsor upon request.  If deemed appropriate by the Sponsor, sufficient samples will be randomly selected from the supply provided by the Sponsor or designee and retained by the s tudy site to meet the retention 
requirements described in U.S. Title 21 Code of Federal Regulations (CFR) 320.38 and 320.63. 
 At the completion of the study, all unused drug supplies (except for retention supplies, if appropriate) will be returned to the Sponsor or designee or disposed of by the study site, per the Sponsor’s or designee’s written instructions. 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 41 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 7.2.2 DOSE PREPARATION AND ADMINISTRATION 
Each unit dose will be prepar ed by qualified clinical staf f based on the study randomization that 
will be provided by a Covance biostatistician . 
 
Appropriate unit doses, as described above, will be administered to subjects in ascending order based on the subjects’ number.  Although the timing of events requires tha t each subject will be 
consistently administered the appropriate dose at specific times, the exact dose time of consecutive subjects may be staggered to obviate the need to have all subjects on precisely the same study schedule.   For each dose, the subject ’s actual time will be recorded in the source 
documents and transcribed into the e CRFs. 
 Except as part of dose administration or as part of a scheduled meal,  subjects will restrict their 
consumption of water for 1 hour prior to dose and for 2 hours postdose; at all other times during the study, subjects may consume water ad libitum.  
7.2.2.1 Part 1 and Par t 2 
In both parts of the study, each dose will be administered orally with approximately 240 mL 
room temperature water.   A hand and mouth check will be performed to verify that the dose 
administered was swallowed.  
 
In Part 1, subjects will receive a standard meal starting 30 minutes prior to dosing which must 
have been entirely consumed within 25 minutes.  In Part 2, d oses will be preceded by an 
overnight fast (i.e., at least 8 hours) from food (not including water) and will be followed by a 
fast from food (not including water) for at least 4  hours postdose.  
 Cases of GDC-0134 accidental overdose or medication error , along with any associated AE s, 
should be report ed as described in Section 8.4.3. 
 Details regarding standard meal administration in Part 1 (including, but not limited to, meal start date/time, meal completion da te/time, and estimated percentage of meal consumed [if not 
entirely consumed]) will be recorded.  
7.3 REMOVAL OF STUDY BLIND  
Not applicable; this is an open-label study and will not be blinded. 
Clinical Protocol 
Covance Study 8398091 CONFIDENTIAL 
Protocol GP40957 
 
 
Final:  19 December 2018 Page 42 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 7.4 DIET, FLUID, AND ACTIVITY CONTROL 
Subjects will refrain from use of tobacco- or nicotine-containing products  (including, but not 
limited to, cigarettes, e-cigarettes, pipes, ciga rs, chewing tobacco, nicotine patches, nicotine 
lozenges, and nicotine gum) with in 6 months prior to Check-in (D ay -1) for their first treatment 
period and during the entire study. 
 Subjects will abstain from consuming alcohol- or caffeine-containing foods and beverages for 
72 hours prior to their Check-in (Day -1) to their first study period until Study Completion/ET, 
unless deemed acceptable by the PI.  Subjects will abstain from consuming grap efruit, grapefruit-containing products, and 
pomegranate, pomelo, and star fr uit juice/products from 7 days prior to Check-in (Day -1) for 
their first treatment period and during the entire study duration. 
 Subjects will refrain from strenuous exercise from 48 hours prior to Check-in (Day -1) for their first treatment period and during the period of co nfinement at the study site and will otherwise 
maintain their normal level of physical activity throughout the enti re study (i.e., will not begin a 
new exercise program or participate in any unusually strenuous  physical exertion). 
 With the exception of dosing, as applicable, while confined at the study site, subjects will receive 
a standardized diet at scheduled times that do not conflict with other study-related activities. 
 Doses will be preceded by an overnight fast (i.e., at least 8 hours) from food (not including water) and will be followed by a fast from f ood (not including water) for at least 4 hours 
postdose, or will be preceded by a standard meal prior to dosing, according to the randomization scheme and as detailed in Section 7.2.2.1.  Except as part of dose administration, subjects will restrict their consumption of water for 1 hour pr ior to dose and for 2 hours postdose; at all other 
times during the study, subjects ma y consume water ad libitum. 
 Subjects will remain seated/standing upright fo r 1 hour following each dose administered, except 
as necessitated by the occurrence of an AE(s) and/or study procedures. 
7.5 CONCOMITANT MEDICATIONS 
Concomitant therapy consists of any prescrip tion medications, herbal, vaccines, topical 
medications, or over-the-counter preparations, including herbal or  dietary supplements taken by 
a subject in addition to protocol -mandated treatment at any time from Check-in (Day -1) for their 
first treatment period through Study Completion. 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 43 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 Subjects will not have received any investigational study drug  within 5 half-lives (if known), or 
30 days (small molecule) or 90 days (biologic), whichever is longer, prior to their first treatment 
period. 
 Subjects will refrain from the use of any prescription medications during the interval from 
14 days prior to Check- in (Day -1) for their first treatment period  and for the entire study 
duration, unless deemed acceptable by the PI (use of HRT or thyroid replacement is acceptable) .  
Subjects will refrain from the u se of strong inhibitors and inducers of CYP3A4/5 and UGT 
enzymes within 14 days prior to Period 1 Check-in (Day -1) for their first treatment period  until 
Study Completion, and alternate medicati ons should be considered where possible. 
 In addition, subjects will refrain from the use of any over- the-counter non-prescription 
medications (including vitamins ; minerals ; and phytotherapeutic-, herbal- , and plant -derived 
preparations) from 14 days prior to Check- in (Day -1) for their first treatment period  and for the 
entire study duration, unless deemed acceptable by the PI (acetaminophen [paracetamol] is 
acceptable and may be administered as needed up to 0.5 to 1 g every 4 to 6 hours [ maximum 
3 g/day] but should be avoided from Check-in [Day - 1] for their first treatment period to the end 
of the study).  Use of thyroid medication or ophthalmic drops or other ophthalmic procedures (as part of the fundoscopic exam) is acceptable.  Subjects will not use  acid reducing medications 
(PPIs, H2 receptor anatagonists, etc) within 14 days prior to Check- in (Day -1) for their first 
treatment period  and during the entire study duration.  As an alternative, antacids may be 
allowed at lea st 4 hours before or after dose.  
 Subjects will not have had any vaccines (including seasonal flu and H1N1 vaccines) within 
14 days prior to the Check-in (Day -1) for their first treatment period . 
 Subjects will not take oral antibiotics within 4 weeks or intravenous antibiotics withi n 8 weeks 
prior to the Screening evaluation.  
 Subjects who have taken drugs of abuse (including opioids) within 4 weeks of Screening or during the entire study will be excluded from this study.  The administration of any other concomitant medications during the study is prohibited without prior approval of the PI , unless its use is deemed necessary in a medical emergency.  Any 
medication taken by a subject during the course of the study and the reason for its use will be documented in the source documents and the e CRF. 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 44 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 7.6 PHARMACOKINETIC BLOOD AND URINE SAMPLE COLLECTION AND 
PROCESSING  
Blood samples for PK analysis of GDC-0134 leve ls will be collected via an indwelling catheter 
and/or via direct venipuncture using Vacutainer evacuated collection tubes.  Blood samples will 
be collected at the timepoints listed in Table 7-1, Table 7-2, and Table 7-3. 
 
Processing, storage, and shipping instructions for these PK blood samples are presented in a separate Laboratory M anual. 
 After the plasma  and urine samples collected in the study are analyzed for GDC-0134 
concentrations, any residual samples may be used for analysis such as metabolite profiling and 
identification, interacting drug concentration measurements, ex vivo protein binding, or development of PK or PD  assays.  Left over PK samples will be destroyed no later than 5  years 
after the final Clinical Study Report has been completed .  When a subject withdraws from the 
study, samples collected prior to the date of withdrawal may still be analyzed, unless the subject specifically requests in writing that the samples be destroyed or local laws require destruction of 
the samples.  However, if samples have been tested prior to withdrawal, results from those tests 
will remain as part of the overall research data.   
 Urine samples for PK analysis will be collected  at the time intervals indicated in Table  7-1 and 
Table 7-2. 
 The weight of the pooled urine collected during each sampling interval will be recorded. Further details will be provided in the Laboratory Manual. 
7.7 ANALYTICAL METHODOLOGY 
Plasma and urine concentrations of GDC-0134 will be determined by Covance Laboratories  
using a validated (plasma) and qualified (urine) analytical procedure.  
 7.8 CLINICAL LABORATORY EVALUATIONS  
Clinical laboratory evaluations (including chemistry panel fasted at least 8 hours, CBC, UA, and 
coagulation profile ) will be colle cted at the timepoints listed in Table 7-1 and Table  7-2. 
 Screens for a hepatitis panel  and HIV antibody will be performed at Screening.  A drug screen 
for selected drugs of abuse (not including alcohol) will be performed at Screening and repeated 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 45 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 (but including an alcohol breath or urine test ) at Check -in (Day -1) for each study period.  A 
serum qualitative pregnancy test (females only) and FSH test (postmenopausal females only) will 
be performed at the timepoints specified in Table 7-1 and Table  7-2. 
 
Tuberculosis testin g will be performed for all subjects at Screening using the following criteria: 
• QuantiFERON TB Gold is an acceptable screening assay for latent mycobacterium  
tuberculosis  infection;  
• An indeterminate QuantiFERON TB Gold test should be repeated. Indeterminate results 
may also be confirmed by a PPD skin t est; 
o A positive PPD tuberculin skin test reaction is considered ≥10 mm (or ≥5 mm in 
subjects receiving the equivalent of > 15 mg/day of prednisone); 
• A positive QuantiFERON TB Gold test should be considered a positive diagnostic TB 
test; 
• An indeterminate QuantiFERON TB Gold test followed by a negative QuantiFERON TB Gold test should be considered a negative diagnostic TB test;  
• If a negative TB screening test has been documented within 3 months of Screening, no 
new test is needed.  
7.9 SAMPLES FOR THE RESEARCH BIOSAMPLE REPOSITORY  
7.9.1 OVERVIEW OF THE RESEARCH BIOSAMPLE REPOSITORY  
The Research Biosample Repository (RBR)  is a centrally administered group of facilities used 
for the long-term storage of human biologic specimens, including body fluids, solid tissues, and derivatives thereof (e.g., DNA, RNA, proteins, and/or peptides).  The collection , storage, and 
analysis of RBR specimens will facilitate the rational design of new pharmaceutical agents and 
the development of diagnostic tests, which may allow for individualized drug therapy for subjects in the future.  Specimens for the RBR will be collected from subjects who give specific consent to participate 
in this research.  The RBR specimen will be used to achi eve the following objectives: 
• To study the association of biomarkers with efficacy, AEs, or disease progression;  
• To increase knowledge and understanding of disease biology; 
• To study drug response, including drug effects and the processes of drug absorption and 
disposition; 
• To develop biomarker or diagnostic assays and establish the performance characteristics 
of these assays.  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 46 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 7.9.2 APPROVAL BY THE INSTITUTIONAL REVIEW BOARD  
Collection and submission of biological samples to the RBR is contingent upon the review and 
approval of the exploratory research and the RBR portion of the ICF by each site’s I nstitutional 
Review Board (IRB)  and, if applicable, an appropriate regulatory body.  If a site has not been 
granted approval for RBR sampling, Sections 7.9 through 7.9.7 of this protocol will not be 
applicable at that site.  
7.9.3 MANDATORY SAMPLES FOR WHOLE GENOME SEQUENCING SAMPLE 
COLLECTION 
A mandatory whole blood sample will be collected for DNA extraction to enable W GS and may 
be sent to one or more laboratories for analysis.   The WGS  sample is considered an RBR sample.  
 For sampling procedures, storage conditions, and shipment instructions, see the Laboratory Manual.  The RBR specimens will be stored until they are no longer needed or until they are exhausted.  
However, the RBR storage period will be in accordanc e with the IRB/EC -approved ICF and 
applicable laws (e.g., health authority requirements).  When a subject withdraws from the study, samples collected prior to the date of withdrawal may still be analyzed, unless the subject specifically requests in writing  that the samples be destroyed or local laws require destruction of 
the samples.   However, if samples have been tested prior to withdrawal, results from those tests 
will remain as part of the overall research data.  
7.9.4 CONFIDENTIALITY  
Specimens and associated data will be labeled with a unique subject identification number. 
 Subject medical information associated with RBR specimens is confidential and may be 
disclosed to third parties only as permitted by the ICF  (or separate authorization for use and 
disclosure of personal health information) signed by the subject, unless permitted or required by 
law. 
 Given the complexity and exploratory nature of the analyses, data derived from RBR specimens will generally not be provided to study PI s or subjects unless requi red by law.  The aggregate 
results of any conducted research will be available in accordance with the effective Sponsor policy on study data publication.  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 47 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 Data generated from RBR specimens must be available for inspection upon request by 
representatives of  national and local health authorities, and Sponsor monitors, representatives, 
and collaborators, as appropriate. 
 Any inventions and resulting patents, improvements, and/or know-how originating from the use of the RBR data will become and remain the exclu sive and unburdened property of the Sponsor, 
except where agreed otherwise.  
7.9.5 CONSENT TO PARTICIPATE IN THE RESEARCH BIOSAMPLE 
REPOSITORY 
The ICF will contain a separate section that addresses participation in the RBR.  The PI  or 
authorized designee will explain to each subject the objectives, methods, and potential hazards of participation in the RBR.  Subjects will be told that they are free to refuse to participate and may 
withdraw their specimens at any time and for any reason during the storage period (the withdrawal of their RBR specimen will coincide with withdrawal from the study).  A separate, 
specific signature will be required to document a subject’s agreement to provide RBR specimens 
for WGS. 
 The PI (or designee) sh ould document whether or not the subject has given consent to participate 
and (if applicable) the date(s) of consent, by completing the RBR Research Sample Informed 
Consent eCRF.  
 In the event of an RBR participant’s death or loss of competence, the participant’s specimens and 
data will continue to be used as part of the RBR research. 
7.9.6 WITHDRAWAL FROM THE RESEARCH BIOSAMPLE REPOSITORY  
Subjects who give consent to provide RBR specimens have the right to withdraw their specimens 
from the RBR at any time and for any reason.  If a subject wishes to withdraw consent to the 
testing of their specimens, the PI  must inform the Medical Monitor in writing of the subject’s 
wishes using the appropriate RBR Subject Withdrawal Form and, if the trial is ongoing, must 
enter the date of withdrawal on the RBR Research Sample Withdrawal of Informed Consent 
eCRF.  The subject will be provided with instructions on how to withdraw consent after the trial 
is closed.  A subject’s withdrawal from this study  does not, by itself, constitute withdrawal of 
specimens from the RBR. 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 48 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 7.9.7 MONITORING AND OVERSIGHT 
The RBR specimens will be tracked in a manner consistent with Good Clinical Practice (GCP) 
by a quality-controlled, auditable, and appropriately- validated laboratory information 
management system to ensure compliance with data confidentiality as well as adherence to authorized use of specimens as specified in this protocol and in the ICF.  Sponsor monitors and auditors will ha ve direct access to appropriate parts of records relating to subject participation in 
the RBR for the purposes of verifying the data provided to the Sponsor.  The site will permit 
monitoring, audits, IRB review, and health authority inspections by providing direct access to source data and documents related to the RBR samples. 
7.10 12-LEAD ELECTROCARDIOGRAMS  
Resting 12- lead ECGs will be recorded after the subject has been supine and at rest for at least 5 
minutes at the times  Table 7-1 and Table 7-2. 
 Single 12- lead ECGs will be repeated twice, and an average taken of t he three readings, if any of 
the following criteria apply:  
• QT interval corrected through use of Fridericia’s formula  (QTcF) value >470 msec  
• PR interval >210 msec 
• QRS complex >120 msec 
• QTcF change from the baseline (predose) is > 60 msec.  
 Additional 12-lead ECGs may be performed at other times if judged to be clinically appropriate or if the ongoing review of the data suggests a more detailed assessment of ECGs is required.  
The PI (or designee) will perform a clinical assessment of each 12 -lead ECG.  
 To minimize variability in autonomic tone and heart rate, subjects will rest quietly and in a supine position for at least 5 minutes prior to recording the ECG. Blood draws, other procedures, activity, and environmental distractions (e.g., tele vision, radio, conversation) should be avoided 
during the pre-ECG resting period and between ECG recordings, to minimize variability due to the effects of activity and stress on cardiac electrophysiology.  Whenever possible, ECG tracings 
for each subject should be obtained from the same type of machine throughout the study.  When 12- lead ECGs are scheduled at the same time as blood draws and vital signs, the blood 
draws will be obtained at the scheduled timepoint, and the 12- lead ECGs  and vital signs will b e 
obtained as close to the scheduled blood draw as possible , but prior to the blood draw (order of 
assessments = ECGs, vital signs, blood samples) . 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 49 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 7.11 VITAL SIGNS  
Vital signs (including oral temp erature, respiratory rate, and supine blood pressure and pulse) 
will be obtained at the timepoints specified in Table 7-1 and Table 7-2. 
 
Supine blood pressure and pulse will be obtained after the subject has been supine for at least 5 minutes.  When vital signs are scheduled at the same time as blood draws, the blood draws w ill 
be obtained at the scheduled timepoint, and the vitals will be obtained as close to the scheduled 
blood draw as possible, but prior to the blood draw. 
7.12 HOW DO YOU FEEL? INQUIRY 
Subjects will be asked a non -leading HDYF? question such as “Have there been any changes in 
your health status since Screening/since you were last asked?” once daily on the days specified 
in Table 7-1 and Table  7-2.  Subjects will also be encouraged to voluntarily report AEs occurring 
at any other time during the study.  See Section 8.3  and Section  8.4 for reporting requirements 
for AEs and SAEs, respectively. 7.13 PHYSICAL EXAMINATIONS  
A routine physical examination will be performed at the timepoints specified in Table  7-1 and 
Table 7-2. 
 
A routine physical examination will consist of an assessment of general appearance, skin, 
thorax/lungs, abdomen, lymph nodes, head, ears, eyes, nose, throat, neck (including thyroid); and cardiovascular,  musculoskeletal, and neurological systems.  The PI or designee may conduct 
unscheduled abbreviated physical examinat ions if required. 
 
7.14 OPHTHALMOLOGY ASSESSMENTS  
During the screening period, a fundoscopic examination will be performed by a qualified 
optician/ophthalmologist as per the local standard of care.  
 The following assessments will be conducted at the times indicated in Table  7-1 and Table  7-2: 
• Best-corrected visual acuity at a distance of 4 meters 
• Near visual acuity using a card  
• Visual field examination  
 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 50 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 Subjects are allowed to use their own glasses for visual acuity and visual field assessments.  If a 
subject has a 2 -line decrease in visual acuity, t hey will be referred for an ophthalmology 
assessment.  Additional ophthalmology assessments may be conducted during the study at the 
discretion of the PI . 
7.15 CLINIC DISCHARGE PROCEDURES  
Refer to Table 7-1 and Table  7-2 for procedures performed on the days of Discharge. 
7.16 STUDY COMPLETION/EARLY TERMINATION PROCEDURES  
Refer to Table 7-1 and Table  7-2 for procedures performed at  Study Completion or at ET. 
8 ADVERSE EXPERIENCES  
8.1 SAFETY PARAMETERS AND DEFINITIONS  
Safety assessments will consist of monitoring and recording AEs, including SAEs and AE SIs, 
performing protocol- specified safety laboratory assessments,  measuring protocol- specified vital 
signs, and conducting other protocol- specified tests that are deemed critical to the safety 
evaluation of the study.  The Sponsor or its designee is responsible for reporting relevant SAEs to the competent authority, other applicable regulatory authorities, and participating PI s, in 
accordance with International Conference on Harmonisation/International Council for Harmonisation  (ICH) guidelines, Food and Drug Administration ( FDA) regulations, European 
Clinical Trials Directive (Directive  2001/20/EC), and/or local regulatory requirements.  
 Certain types of events require immediate reporting to the Sponsor, as outlined in Section  8.4. 
8.1.1 ADVERSE EVENTS 
According to the ICH Guideline for GCP, an AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following: 
• Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, whether 
or not considered related to the medicinal product; 
• Any new disease or exacerbation of an existing disease (a worsening in the character, 
frequency, or severity of a known condition); 
• Recurrence of an intermittent medical condition (e.g., headache) not present at baseline; 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 51 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 • Any deterioration in a laboratory value or other clinical test (e.g., ECG, X- ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study drug; 
• AE that are related to a protocol-mandated intervention, including those that occur prior 
to assignment of study treatment (e.g., screening invasive procedures such as biopsies).  
8.1.2 SERIOUS ADVERSE EVENTS (IMMEDIATELY REPORTABLE TO THE 
SPONSOR)  
An SAE is any AE  that meets any of the following criteria : 
• Is fatal (i.e., the AE actually causes or leads to death);  
• Is life-threatening (i.e., t he AE, in the view of the PI , places the subject at immediate risk 
of death); this does not include any AE that had it occurred in a more severe form or was 
allowed to continue might have caused death; 
• Requires or prolongs inpatient hospitalization; 
• Results in persistent or significant disability /incapacity ( i.e., the AE results in substantial 
disruption of the subject’s ability to conduct normal life functions); 
• Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to study drug; 
• Is a significant  medical event in the PIs judgment (e.g., may jeopardize the subject or 
may require medi cal/surgical intervention to prevent one of the outcomes listed above ). 
 
All AEs that do not meet any of the criteria for serious should be regarded as non- serious AEs. 
 The terms “severe” and “serious” are not synonymous. Severity refers to the intensity of an AE 
(e.g., rated as mild, moderate, or severe, according to National Cancer Institute Common Terminology Criteria for Adverse Events); the event itself may be of relatively minor medical significance (such as severe headache)  without any further findings.  An event should be 
considered “serious” only if it meets the regulatory criteria outlined in the above -mentioned 
paragraph outlining seriousness criteria.  Seriousness (not severity) serves as the guide for defining regulatory reporting obligations.  Severity and seriousness need to be independently assessed for each AEs recorded on the eCRF . 
 Serious AEs are required to be reported by the PI  to the Sponsor via the Covance project 
manager immediately (i.e., no more than 24 hours after learning of the event; see Section 8.4.2 
for reporting instructions).  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 52 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 8.1.3 ADVERSE EVENTS OF SPECIAL INTEREST (IMMEDIATELY REPORTABLE 
TO THE SPONSOR)  
Adverse events of special interest  are required to be reported by the PI  to the Sponsor via the 
Covance project manager  immediately (i.e., no more than 24 hours after learning of the event; 
see Section  8.4.2 for reporting instructions).  The AESI for this study are as follows:  
 
• Clinically significant peripapillary or optic disc swelling on funduscopic 
examination, as determined by the local site PI /ophthalmologist 
• Clinically significant functional visual change from baseline, as 
determined by the local site PI/ophthalmologist 
 
• Cases of potential drug-induced liver injury that include an elevated alanine 
aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either 
an elevated bilirubin or clinical jaundice, as defined by Hy’s Law (see Section 8.3.1.6); 
• Suspected transmission of an infectious agent by the study drug as defined below: 
o Any organism, virus, or infectious particle (e.g., prion protein tr ansmitting 
transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is considered an infectious agent. A transmission of an infectious agent may be suspected from clinical symptoms or laboratory findings that indicate an infection in a subje ct exposed to a medicinal product. The term applies only when a 
contamination of the study drug is suspected. 
 
8.2 METHODS AND TIMING FOR CAPTURING AND ASSESSING SAFETY 
PARAMETERS  
The PI is responsible for ensuring that all AEs (as defined in Section  8.1) are recorded on the AE 
eCRF and reported to the Sponsor via the Covance project manager in accordance with protocol 
instructions  (see Section 8.4.2). 
 For each AE recorded on the AE eCRF, the PI will make an assessment of seriousness (see 
Section 8.1.2 for seriousness criteria), severity, and causality (see Section 8.2.3). 
8.2.1 ADVERSE EVENT REPORTING PERIOD  
Principal Investigators  will seek information on AEs at each subject contact.   All AEs, whether 
reported by the subject or noted by study personnel, will be recorded in the subject’s medical record and on the AE eCRF. 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 53 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018  
After informed consent  has been obtained but pr ior to initiation of study drug , only SAEs 
caused by a protocol-mandated intervention (e.g., discontinuation of medications) will be reported (see Section 8.4.2 for instructions for reporting SAEs).  After initiation of study drug administration, all AEs  will be re ported until 28 days after the final dose. 
 Instructions for reporting AEs that occur after the AE reporting period are provided in Section 8.5. 
 The PI is not required to actively monitor subjects after the study has ended  or for AEs after the 
end of the AE reporting period (defined as 28 days after the final dose of study drug, whichever 
is longer).  However, the Sponsor should be notified if the PI  becomes aware of any death, other 
SAEs, or AESIs  occurring after the end of the AE reporting period that are believed to be related 
to prior study drug treatment.  The Sponsor should also be notified if the PI becomes aware of 
the development of cancer or a congenital anomaly/birth defect in a subsequently conceived offspring of a female subject  exposed to study drug. 
8.2.2 ELICITING ADVERSE EVENT INFORMATION  
A consistent methodology of non-directive questioning should be adopted for eliciting AE information at all subject evaluation timepoints.  Examples of non-directive questions include the following: 
• “How have you felt since your last clinic visit?” 
• “Have you had any new or changed health problems since you were last here?” 
8.2.3 ASSESSMENT OF SEVERITY OF ADVERSE EVENTS  
The World Health Organization (WHO) toxicity grading scale will be used for assessing AE severity. Table  8-1 will be used for assessing severity for AEs that are not specifically listed in 
the WHO toxicity grading scale.  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 54 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 Table  8-1 Adverse Event Severity Grading Scale for Events Not Specifically Listed in 
WHO Toxicity Grading Scale 
Grade Severity 
1 Mild; transient or mild discomfort ( <48 hours); no medical intervention or therapy required  
2 Moderate; mild to moderate limitation in activity; some assistance may be needed; no or 
minimal medical intervention or therapy required  
3 Severe; marked limitation in activity; some assistance usually required; medical intervention or 
therapy required; hospitalization possible  
4 Life-threatening; extreme limitation in activity; significant assistance required; significant 
medical intervention or therapy required, hospitalization or hospice care  probable 
Notes:  Developed by the Division of Microbiology and Infectious Diseases.  
Regardless of severity, some events may also meet seriousness criteria. Refer to definition of an SAE (see 
Section 8.1.2). 
 
8.2.4 ASSESSMENT OF CAUSALITY OF ADVERSE EVENTS  
Principal Investigators  should use their knowledge of the subject, the circumstances surrounding 
the event, and an evaluation of any potential al ternative causes to determine whether an AE is 
considered to be related to the study drug, indicating “yes” or “no” accordingly.  The following 
guidance should be taken into consideration (see also Table  8-2): 
• Temporal relationship of event onset to the initiation of study drug; 
• Course of the event, with special consideration of the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (as applicable); 
• Known association of the event with the study drug or with similar treatments; 
• Known association of the event with the disease under study; 
• Presence of risk factors in the subject  or use of concomitant medications known to 
increase the occurrence of the event ; 
• Presence of non -treatment- related factors that are known to be associated with the 
occurrence of the event . 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 55 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 Table  8-2 Causal Attribution Guidance  
Is the adverse event suspected to be caused by the study drug based on facts, evidence, science- based rationales, and 
clinical judgment?  
YES There is a plausible temporal relationship between the onset of the adverse event  and administration of the 
study drug, and the adverse event cannot be readily explained by the subject’s clinical state, intercurrent 
illness, or concomitant therapies; and/o r the adverse event  follows a known pattern of response to the 
study drug; and/or the adverse event abates or resolves upon discontinuation of the study drug  or dose 
reduction and, if  applicable, reappears upon re- challenge.  
Principal I nvestigators should apply facts, evidence, or rationales based on scientific principles and 
clinical judgment to support a causal/contributory association with a study drug . 
NO AE will be considered related, unless they fulfill the criteria as specified below.  
Evidence exists that the adverse event has an etiology other than the study drug (e.g., pre-existing medical 
condition, underlying disease, intercurrent illness, or  concomita nt medication); and/or the adverse event 
has no plausible temporal relationship to administration of the study drug  (e.g., cancer diagnosed 2 days 
after first dose of study drug).  
Note:  The PIs assessment of causality for individual adverse event reports is part of the study 
documentation process. Regardless of the “Yes” or “No” causality assessment for individual adverse event 
reports, the Sponsor will promptly evaluate all reported SAEs against cumulative product experience to 
identify and expeditiously communicate possible new safety findings to PIs and applicable regulatory 
authorities. Attribution of SAEs  will be reviewed on an ongoing basis, and may be changed as 
additional clinical data emerges (e.g., reversibility of adverse event , new clin ical findings in subject  
with adverse event , effects of re -treatment, and AE in other subject s). 
 
8.3 PROCEDURES FOR RECORDING ADVERSE EVENTS  
8.3.1 RECORDING ADVERSE EVENTS ON THE CASE REPORT FORM  
Principal Investigators should use correct medical terminology /concepts when recording AEs on 
the AE eCRF . Colloquialisms and abbreviations should be avoided. 
 
All AEs should be recorded on the AE eCRF page. If the AE qualifies as an SAE or non- serious 
AESI, the PI should record all case details that can be gathered immediately (i.e., within 24 hours 
after learning of the event) on a paper Clinical Trial SAE/AE SI Reporting F orm.  The completed 
paper Clinical Trial SAE/AESI Reporting Form and s afety fax coversheet  should be emailed to 
Roche Safety Risk Management  via the Covance project manager  within 24 hours of learning of 
the event (see Section 8.4.2).   The AE and SAE eCRF should also be completed within this 
timeframe.  It is important that the information on the SAE Reporting F orm and AE and SAE 
eCRF is consistent and identical.  
 Only one AE term  should be recorded in the event field on the AE eCRF. 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 56 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 8.3.1.1 DIAGNOSIS VERSUS SIGNS AND SYMPTOMS  
If known, a diagnosis should be recorded on the AE eCRF rather than individual signs and 
symptoms ( e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated 
transaminases).   However, if a constellation of signs and/or symptoms cannot be medically 
characterized as a single diagnosis or syndrome at the time of reporting, each individual event 
should be recorded on the AE eCRF .  If a diagnosis is subsequently established, all previously 
reported AEs based on signs and symptoms should be nullified and replaced by one AE report based on the single diagnosis, with a starting date that corresponds to the starting date of the first symptom of the eventual diagnosis. 
8.3.1.2 ADVERSE EVENTS THAT ARE SECONDARY TO OTHER EVENTS  
In general, AEs that are secondary to other events (e.g., cascade events or clinical sequelae) 
should be identified by their primary cause, with the exception of severe or serious secondary events.  A medically significant secondary AE that is separated in time from the initiating event 
should be recorded as an independent event on the AE eCRF.  For example: 
• If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF; 
• If vomiting results in severe dehydration, both events should be reported separately on 
the eCRF;  
• If a severe GI hemorrhage leads to renal failure, both events should be reported 
separately on the eCRF;  
• If dizziness leads to a fall and subsequent fracture, all  three events should be reported 
separately on the eCRF;  
• If neutropenia is accompanied by an infection, both events should be reported separately 
on the eCRF. 
 All AEs should be recorded separately on the AE eCRF if it is unclear as to whether the events are associated . 
8.3.1.3 PERSISTENT OR RECURRENT ADVERSE EVENTS  
A persistent AE is one that extends continuously, without resolution between subject evaluation timepoints.  Such events should only be recorded once in the AE eCRF.  The initial severity 
(intensity or grade) of the event will be recorded at the time the event is first reported.  If a 
persistent AE becomes more severe, the most extreme severity should also be recorded on the AE eCRF.  If the event becomes serious, it should be reported to the Sponsor imm ediately (i.e., 
no more than 24 hours after learning that the event became serious; see Section 8.4.2 for 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 57 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 reporting instructions).  The AE eCRF should be updated by changing the event from “non-
serious” to “serious,” providing the date that the event became serious, and completing all data 
fields related to SAEs.  
 A recurrent AE is one that resolves between subject evaluation timepoints and subseq uently 
recurs.  Each recurrence of an AE should be recorded as a separate event on the AE eCRF . 
8.3.1.4 ABNORMAL LABORATORY VALUES  
Not every laboratory abnormality qualifies as an AE.  A laboratory test result should be reported as an AE if it meets any of the fol lowing criteria: 
• Is accompanied by clinical symptoms; 
• Results in a change in study treatment (e.g., dosage modification, treatment interruption, or treatment discontinuation); 
• Results in a medical intervention (e.g., potassium supplementation for hypokalemia) or a 
change in concomitant therapy; 
• Is clinically significant in the PIs judgment. 
 
It is the responsibility  of the PI to review all laboratory findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated laboratory abnormality should be classified as an AE.  
 If a clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., alkaline phosphatase and bilirubin five  times the upper limit of normal ( ULN) associated with 
cholestasis), only the diagnosis (i.e., cholestasis) should be recorded on the AE eCRF. 
 If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, the abnormality itself should be recorded on the AE eCRF, along with a descriptor indicating whether the test result is above or below the normal range (e.g., “ elevated potassium, ” as 
opposed to “abnormal potassium” ).  If the laboratory abnormality can be characterized by a 
precise clinical term per standard definitions, the clinical term should be recorded as the AE.  For 
example, an elevated serum potassium level of 7.0 mEq/L should be recorded as “hyperkalemia.”  Observations of the same clinically significant laboratory abnormality from visit to visit should 
only be recorded once on the AE eCRF (see  Section 8.3.1.3 for details on recording persistent 
AEs). 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 58 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 8.3.1.5 ABNORMAL VITAL SIGN VALUES  
Not every vital sign abnormality qualifies as an AE.  A vital sign result should be reported as an 
AE if it meets any of the following criteria:  
• Is accompanied by clinical symptoms; 
• Results in a change in study treatment (e.g., dosage modification, treatment interruption, 
or treatment discontinuation); 
• Results in a medical intervention or a change in concomitant therapy; 
• Is clinically significant in the judgment of the PI. 
 It is the responsibility  of the PI to review all vital sign findings.   Medical and scientific judgment 
should be exercised in deciding whether an isolated vital sign abnormality should be classified as 
an AE. 
 If a clinically significant vital sign abnormality is a sign of a disease or syndrome (e.g., high 
blood pressure), only the diagnosis (i.e., hypertension) should be recorded on the AE eCRF.  Observations of the same clinically significant vital sign abnormality from visit to visit should only be recorded once o n the AE eCRF (see Section 8.3.1.3 for details on recording persistent 
AEs). 
8.3.1.6 ABNORMAL LIVER FUNCTION TESTS  
The finding of an elevated ALT or AST (>3 × ULN) in combination with either an elevated total bilirubin (>2 × ULN) or clinical jaundice in the absence of cholestasis or other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury (as defined by Hy’s Law).  Therefore,  PIs must report as an AE the occurrence of either of the following: 
• Treatment -emergent ALT or AST >3 × ULN in combination with total bilirubin >2 × 
ULN; 
• Treatment -emergent ALT or AST >3 × ULN in combination with clinical jaundice. 
 The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal laboratory values should be recorded on the AE eCRF (see Section 8.3.1) and reported to the Sponsor 
immediately (i.e., no more than 24 hours after learning of the event), either as an SAE or an AESI (see Section 8.4.2 ). 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 59 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 8.3.1.7 DEATHS  
All deaths that occur during the protocol-specified AE reporting period (see Section 8.2.1), 
regardless of relationship to study drug, will be recorded on the  AE eCRF as well as on the paper 
Clinical Trial SAE Reporting F orm and immediately reported to the Sponsor via the Covance 
project manager (see Section 8.4.2 for reporting instructions) . 
 
Death should be considered an outcome and not a distinct event.  The event or condition that caused or contributed to the fatal outcome should be recorded as the single medical concept on 
the AE eCRF. Generally, only one such event should be reported.  If the cause of death is unknown and cannot be ascertained at the time of reporting, “unexplained death” should be recorded on the AE eCRF.  If the cause of death later becomes available (e.g., after autopsy), “unexplained death” should be replaced by the established cause of death.  The term “sudden death” should not be used unless combined with the presumed cause of death (e.g. “sudden cardiac death”).  
 Deaths that occur after the AE reporting period should be reported as described in Section  8.5. 
8.3.1.8 PRE- EXISTING MEDICAL CONDITIONS  
A pre-existing medical condition is one that is present at the Screening visit for this  study. Such 
conditions should be recorded on the General Medical History  and Baseline Conditions eCRF 
page.  A pre-existing medical condition should be recorded as an AE only if the frequency, severity, or 
character of the condition worsens during the study.  When recording such events on an AE eCRF, it is important to convey the concept that the pre-existing condition has changed by including applicable descriptors ( e.g., “accelerated worsening of  headaches”).  
8.3.1.9 HOSPITALIZATION OR PROLONGED HOSPITALIZATION  
Any AE that results in hospitalization  (i.e., inpatient  admission to a hospital) or prolonged 
hospitalization should be documented and report ed as an SAE  (per the definition of SAE in 
Section 8.1.2) except as outlined below.   An event that leads to hospitalization under the following circumstances should not be reported 
as an AE or SAE : 
• Hospitalization for respite care;  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 60 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 • Hospitalization for a pre-existing condition, provided that all of the following criteria are 
met: 
o The hospitalization was planned prior to the study or was scheduled during the study when elective surgery became necessary because of the expected normal progression of the disease; 
o The subject has not experienced an AE. 
 An event that leads to  hospitalization under the following circumstances is  not considered to be 
an SAE but should be reported as an AE instead:  
• Hospitalization that was necessary because of the subject’s requirement for outpatient 
care outside of normal outpatient clinic operation hours. 
8.4 IMMEDIATE REPORTING REQUIREMENTS FROM PRINCIPAL INVESTIGATOR TO SPONSOR  
Certain events require immediate reporting to allow the Sponsor to take appropriate measures to address potential new risks in a clinical trial.  The PI must report such events to the Sponsor 
immediately via the Covance project manager ; under no circumstances should reporting take 
place more than 24 hours after the PI  learns of the event.   The following is a list of events that 
the PI must report to the Sponsor within 24 hours (see  Section 8.4.2) after learning of the event, 
regardless of relationship to study drug: 
• SAEs (see Section 8.4.2 for further details) ; 
• AESIs (see Section 8.1.3 for further details) ; 
• Pregnancies ( see Section 8.4.2.3 for further details); 
• Accidental overdoses or medication errors (see Section 8.4.3 for details on reporting 
requirements) ; 
 The PI must report new significant follow -up information for these events to the Sponsor 
immediately via the Covance project manager  (i.e., no more than 24 hours after becoming aware 
of the information).  New significant information includes the following:  
• New signs or symptoms or a change in the diagnosis; 
• Significant new diagnostic test results ; 
• Change in causality based on new information; 
• Change in the event’s outcome, including recovery; 
• Additional narrative information on the clinical course of the event. 
 Principal Investigators must also comply with local requirements for reporting SAEs to the local health authority and IRB/EC.  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 61 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 8.4.1 REPORTING REQUIREMENTS FOR FATAL OR LIFE- THREATENING 
SERIOUS ADVERSE EVENTS  
Any life-threatening (e.g., imminent risk of death) or fatal AE that is attributed by the PI  to study 
drug will be telephoned to the Medical Monitor immediately, followed by completion of the 
paper Clinical Trial SAE Reporting Form within 24 hours of learning of the event as described in 
Section 8.4.2.  Medical Monitor :   William Cho , M.D., Ph.D. 
 Genentech, Inc. 
 (650) 225-4087 (Office Telephone No.)  
 ((650) 302-3027 (Mobi le Telephone No.)  
8.4.2 REPORTING REQUIREMENTS FOR ALL SERIOUS ADVERSE EVENTS  
8.4.2.1 EVENTS THAT OCCUR PRIOR TO STUDY DRUG INITIATION 
After informed consent has been obtained but prior to initiation of study drug, only SAEs caused by protocol-mandated intervention should be reported.  The completed paper Clinical Trial SAE/AESI Reporting Form provided to the PI  should be completed and submitted to the Sponsor 
via the Covance project manager immediately (i.e., no more than 24 hours after learning of the 
event), either by faxing or by scanning and emailing the form using the fax number or email address provided below.  The Covance project manager to receive the PI-generated SAE reports:  
Name:  Jaclyn Lowe 
Email Address:  Jaclyn.lowe@covance.com 
608-210-5359 (Office Telephone No.)  214-502-8547 (Mobile Telephone No.)  
 
8.4.2.2 EVENTS THAT OCCUR AFTER STUDY DRUG INITIATION  
After initiation of study drug, SAEs and AESIs  will be reported until 28 days after the final dose 
of study drug. Principal Investigators should record all case details that can be gathered 
immediately on a paper Clinical Trial SAE/AESI  Reporting Form.  The completed paper Clinical 
Trial SAE/AE SI Reporting Form should be completed and submitted to the Sponsor (via the 
Covance project manager ) immediately (i.e., no more than 24 hours after learning of the event), 
either by faxing or by scanning and emailing the form using the fax number or email address 
provided in Section 8.4.2.1.  All information will also need to be entered into the AE eCRF.  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 62 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 Relevant follow-up information should be submitted to Roche Safety Risk Management via the 
Covance project manager  on an updated paper Clinical Trial SAE/AE SI Reporting Form as soon 
as it becomes available and/or upon request.  Any updates to the paper Clinical Trial SAE/AE SI 
Reporting Form must also be updated in electronic data capture ( EDC) on the AE eCRF.  
 Relevant follow-up information should be submitted to Roche Safety Risk Management via the Covance project manager  on an updated paper Clinical Trial SAE/AE SI Reporting Form as soon 
as it becomes available and/or upon request.  Any updates to the paper Clinical Trial SAE/AE SI 
Reporting Form must also be updated in EDC on the AE eCRF. 
8.4.2.3 REPORTING REQUIREMENTS FOR PREGNANCIES  
8.4.2.3.1 PREGNANCIES IN FEMALE SUBJECTS  
Subjects should be females of non- childbearing potential in order to be eligible to enter this 
study.  However, the subject  will be instructed to immediately inform the PI if they become 
pregnant during the study or within 28 days after the final dose of study drug.  A paper Clinical 
Trial Pregnancy Report ing Form should be completed by the PI immediately (i.e., no more than 
24 hours after learning of the pregnancy) and emailed to Roche Safety Risk Management via the 
Covance project manager (see Section 8.4.2 for reporting instructions).  Pregnancy should not be 
recorded on t he AE eCRF.  The PI should discontinue study drug and counsel the subject , 
discussing the risks of the pregnancy and the possible effects on the fetus.  Monitoring of the 
subject should continue until conclusion of the pregnancy.  Any SAEs associated with the pregnancy (e.g., an event in the fetus, an event in the mother during or after the pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the AE eCRF.  In addition, the PI will submit a  paper Clinical Trial Pregnancy Reporting Form when updated information 
on the course and outcome of the pregnancy becomes available. 
8.4.2.3.2 CONGENITAL ANOMALIES/BIRTH DEFECTS AND ABORTIONS  
Any congenital anomaly/birth defect in a child born to a female subject exposed to th e study 
drug should be classified as an SAE, recorded  on the AE eCRF , and reported to the Sponsor 
immediately via the Covance project manager  (see Section 8.4.2 for reporting instructions) (i.e., 
no more than 24 hours after learning of the event; see Section 8.4.2).  Any abortion should be 
reported in the same fashion (as the Sponsor considers abortions to be medically significant 
events). 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 63 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 8.4.3 REPORTING REQUIREMENTS FOR CASES OF ACCIDENTAL OVERDOSE 
OR MEDICATION ERROR  
Accidental overdose and medication error (hereafter collectively referred to as “special 
situations”), are defined as follows:  
• Accidental overdose:  accidental administration of a drug in a quantity that is higher than the assigned dose;  
• Medication error:  accidental deviation in the administration of a drug .  
 In some cases, a medication error may be intercepted prior to administration of the drug. 
 Special situations are not in themselves AEs, but may result in AE s.  Each AE associated with a 
special situation should be recorded separately on the AE eCRF.  If the associated AE fulfills seriousness criteria, the event should be reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section  8.4.2).  For GDC-0134, AEs associated with 
special situation s should be recorded as described below for each situation:  
• Accidental overdose:  Enter the AE term. Check the “Accidental overdose” and 
“Medication error” boxes.  
• Medication error that does not qualify as an overdose:  Enter the AE term. Check the “Medication error” box. 
• Medication error that qualifies as an overdose:  Enter the AE term. Check the “Accidental 
overdose” and “Medication error” boxes.  
 
In addition, a ll special situations associated with GDC-0134, regardless of whether they result in 
an AE, should be recorded on the AE eCRF and reported to the Sponsor immediately 
(i.e., no more than 24 hours after learning of the event).  Special situations should be recorded as 
described below: 
• Accidental overdose:  Enter the drug name and “accidental overdose” as the event term. Check the “Accidental overdose” and “Medication error” boxes.  
• Medication error that does not qualify as an overdose:  Enter the name of the drug 
administered and a description of the error (e.g., wrong dose administered, wrong dosing 
schedule, incorrect route o f administration, wrong drug, expired drug a dministered) as the 
event term.  Check the “Medication error” box. 
• Medication error that qualifies as an overdose:  Enter the drug name and “accidental 
overdose” as the event term.  Check the “Accidental overdose” and “Medication error” 
boxes. Enter a description of the error in the additional case details.  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 64 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 • Intercepted medication error:  Enter the drug name and “intercepted medication error” as 
the event term. Check the “Medication error” box. Enter a description of  the error in the 
additional case details.  
 As an example, an accidental overdose that resulted in a headache would require the completion of two AE  eCRF pages, one to report the accidental overdose and one to report the headache.  
The “Accidental overdose” and “Medication error” boxes would need to be checked on both 
eCRF pages.  
8.4.4 FOLLOW -UP OF SUBJECTS AFTER ADVERSE EVENTS  
8.4.4.1 PRINCIPAL INVESTIGATOR FOLLOW -UP 
The PI should follow each  AE until the event has resolved to baseline grade or better, the event 
is assessed as stable by the PI, the subject is lost to follow -up, or the subject withdraws consent.  
Every effort should be made to follow all SAEs considered to be related to study drug or trial-related procedures until a final outcome can be r eported.  During the study period, resolution of 
AEs (with dates) should be documented on the AE e CRF and in the subject’s medical record to 
facilitate source data verification.  
 All pregnancies reported during the study should be followed until pregnancy outcome. 
8.4.4.2 SPONSOR FOLLOW -UP 
For SAEs , AESI, and pregnancies, the Sponsor or a designee may follow-up by telephone, fax, 
email, and/or a monitoring visit to obtain additional case details  and outcome information (e.g., 
from hospital discharge summaries, consultant reports, autopsy reports) in order to perform an 
independent medical assessment of the reported case. 
8.5 ADVERSE EVENTS  THAT OCCUR AFTER THE ADVERSE EVENT REPORTING 
PERIOD  
At the Study Completion/ET visit or at Clinic Discharge, the PI should instruct each subject to 
report to the PI any subsequent AEs that the subject’s personal physician believes could be 
related to prior study drug treatment or study procedures.  The Sponsor should be notified if the 
PI becomes aware of any SAE that occurs after the end of the AE reporting period (defined as 
28 days after the final dose of study drug) if the event is believed to be related to prior study drug 
treatment.  
 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 65 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 These events should be reported through the use of the AE eCRF.  However,  if the EDC system 
is not available, the PI  should report these events directly to the Sponsor or its designee, by 
faxing or by scanning and emailing the paper Clinical Trial SAE/AE SI Reporting Form using the 
below fax number or email address provided to PI s. 
 
Genentech US Drug Safety Email Address:  us_drug.safety@gene.com  
Fax No.:  (650) 225-4682 
8.5.1 EXPEDITED REPORTING TO HEALTH AUTHORITIES, PRINCIPAL 
INVESTIGATORS, AND INSTITUTIONAL REVIEW BOARDS  
The Sponsor will promptly evaluate all SAEs and AESIs against cumulative product experience to identify and expeditiously communicate possible new safety findings to PI s, IRBs, and 
applicable health authorities based on applicable legislation.  
 To determin e reporting requirements for single AE cases, th e Sponsor will assess the 
expectedness of these events using the following reference document(s):  
 
• GDC-0134 IB 
 The Sponsor will compare the severity of each event and the cumulative event frequency reported for the study with the severity and frequency reported in the applicable reference document.  Reporting requirem ents will also be based on the PIs  assessment of causality and seriousness, 
with allowance for upgrading by the Sponsor as needed.  The IRB will  be notified by the investigative site in writing (e.g., email) within the timeframe 
required per local IRB regulations for when a reportable AE is first recognized or reported.   In 
addition, a copy of the written confirmation or summary of the AE, as submitted to the Sponsor, will also be submitted to the IRB within that same timeframe from when the AE is first recognized or reported.  The IRB Serious and Unexpected AE Submission Form will be 
completed and submitted with the copy of the written confirmation or summary of the AE. 
9 STATISTICAL ANALYSES  
The Safety Population will consist of all subjects who received the study drug and have at least 
one postdose safety assessment.  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 66 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 The PK Population will consist of all subjects who received the study drug and have at least 
one evaluable postdose PK sample.   A subject will be excluded from the PK summary statistics 
and statistical analysis (where applicable) if the subject has an AE of vomiting that occurs at or 
before 2 times median tmax. 
 
Baseline is defined as the last result prior to the study drug administration  on Day 1.  As 
necessary, baseline will be further defined in the Statistical Analysis Plan (SAP ). 
9.1 SAFETY AND TOLERABILITY ANALYSIS  
Safety will be assessed by a review of AEs, physical examinations, vital signs, clinical laboratory 
assessments, ophthalmologic assessments, and ECGs.  Clinical laboratory assessments, v ital 
signs (including oral temperature, respiratory rate, and supine  blood pressure and pulse), weight 
data, ophthalmologic assessments, and ECGs  will be listed by subject number and scheduled 
time. Changes from baseline will be summarized.  
 Verbatim descriptions of AEs will be coded according to current Medical Dictionary for Regulatory Activities version 20.0 (or higher) guidelines. A dverse events will be summarized. 
Adverse events of special interest  that could indicate hypersensitivity reactions will be 
summarized separately. Enrollment and discontinuations from the study will be summarized overall. Demographi cs and baseline characteristics such as age, sex, and BMI will be 
summarized overall.  
9.2 PHARMACOKINETIC ANALYSIS  
The following PK parameters will be derived from the  plasma  concentrations of GDC-0134 
using the model independent approach:  
C
max maximum observed concentration  
tmax time to maximum observed concentration 
AUC0-t area under the concentration- time curve from Hour 0 to the last 
measurable concentration, calculated using the linear trapezoidal rule for increasing concentrations and the logarithm ic rule for 
decreasing concentrations 
AUC
0-∞ area under the concentration-time curve extrapolated to infinity, 
calculated using the formula:  
AUC0-∞ = AUC 0-t + 
zt
λC 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 67 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 where C t is the last measurable concentration and λz is the apparent 
terminal elimination rate constant  
λz apparent terminal elimination rate constant, where λz is the 
magnitude of the slope of the linear regression of the log 
concentration versus time profile during the terminal phase 
t1/2 apparent terminal elimination half -life (whenever possible), where 
t1/2 = natural log (ln )2/λz 
CL/F apparent systemic clearance, calculated as dose/ AUC 0-∞ 
Vz/F apparent volume of distribution during the terminal phase, 
calculated as CL/F/ λz 
 The following PK param eters will be derived from urine concentrations of GDC -0134:  
A
eu amount excreted in urine over a sampling interval 
Total A eu cumulative amount excreted in urine 
%Feu percentage of dose excreted in urine over a sampling interval  
Total %F eu cumulative percentage of dose excreted in urine 
CLR renal clearance 
 Pharmacokinetic calculations will be performed, if appropriate, using commercial software such as Phoenix WinNonlin ( Certara Inc., Version 6.4 or higher ). 
 Other parameters may be added as appropriate. Final PK parameters reported will be detailed in the SAP. 
 Pharmacokinetic analysis will use actual times as recorded on the eCRF. Other data handling 
procedures will be detailed in the SAP. 
9.3 WHOLE GENOME SEQUENCING ANALYS IS 
The WGS data will be analyzed in the context of this study and explored in aggregate with data 
from other studies to increase researcher ’s understanding of disease pathobiology and guide the 
development of new therapeutic approaches. 9.4 INTERIM ANALYSIS  
No interim analyses are planned for this study. 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 68 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 9.4.1 OPTIONAL INTERIM ANALYSIS  
Given the hypothesis-generating nature of this study, the Sponsor may choose to conduct interim 
analyses.  The decision to conduct an optional interim analysis and the timing of the analysis will 
be documented in the Sponsor’s trial master file prior to the conduct of the interim analysis.  The 
interim analysis will be performed and interpreted by Sponsor study team personnel.  
9.5 STATISTICAL ANALYSIS OF PHARMACOKINETIC DATA  
Descriptive statistics (mean, median, minimum, maximum, standard deviation, geometric mean, and geometric coefficient of variation) will be calculated for all PK parameters and PK concentration data.  
 The primary parameters for analysis will be AUC
0-∞ and C max of GDC-0134. A linear mixed 
model will be applied to analyze the log- transformed primary PK parameters. The model 
assumes fixed effects for formulation, period, and sequence, and a random e ffect for subject 
within sequence. Estimates of geometric mean ratios on the original scale, together with the corresponding 90% CIs, will be derived for the comparisons between Test and Reference treatments.  
 Time to maximum observed concentration will be  analyzed by using Wilcoxon signed-rank test, 
and Hodges- Lehmann estimate to generate the difference in medians between treatments (Test- 
Reference) and 90% CI of the median difference.  
 All calculations will be performed using SAS
® version 9.4 or greater. 
 Specification of PK parameters for analysis; statistical level of significance to be used; criteria for study termination; procedures for accounting for missing, unused, or spurious data; procedures for reporting deviations from the original statistical plan; and selection of subjects to be included in the analyses population(s) will be presented in the Clinical Study Report and/or SAP as appropriate.  Statistical analyses details will be included in the SAP.  
 
9.6 STATISTICAL ANALYSES OF SAFETY DATA  
Descriptive statistics will be used for the safety parameters.   No formal statistical analyses are 
planned. 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 69 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 9.7 SAMPLE SIZE  
The sample size chosen for this study was based upon precedent set by other PK studies of 
similar nature and was n ot based on power calculations.  
9.8 QUALITY CONTROL AND QUALITY ASSURANCE  
Quality control and quality assurance will be performed according to Covance Standard Operating Procedures or per client request and as applicable according to the contract between Covance and the Sponsor. 
10 ADMINISTRATIVE ASPECTS  
10.1 CHANGE IN PROTOCOL 
There will be no alterations in the protocol without agreement between the Sponsor and the PI . 
 
There will be no alterations in the protocol affecting subject safety without the express written approval of the Sponsor, PI, and the IRB (see F orm FDA 1572). 
10.2 PRINCIPAL INVESTIGATOR MEETING; SITE INITIATION  
Prior to the start of the clinical study, the representative(s) of the Sponsor will meet with the PI(s) and appropriate clinical staff to familiarize the PI and clinica l staff with the materials 
necessary for conducting the clinical study. 
10.3 DISCLOSURE  
All information provided regarding the study, as well as all information collected  and 
documented during the course of the study, will be regarded as confidential.  The PI  agrees not to 
disclose such information in any way without prior written permission from the Sponsor. 
 Any publication of the results, either in part or in total (e.g., articles in journals or newspapers, oral presentations, abstracts) by the PI(s) or their  representative(s), shall require prior notification 
and review, within a reasonable timeframe, by the Sponsor, and cannot be made in violation of the Sponsor’s confidentiality restrictions or to the detriment of the Sponsor’s intellectual property rights.  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 70 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 10.4 MONITORING (CLINICAL RESEARCH A SSOCIATE ) 
The Sponsor will designate a Sponsor’s Study Monitor who will be responsible for monitoring 
this clinical trial.  The Sponsor’s Study Monitor will monitor the study conduct, proper e CRF 
and source documentation completion and retention, and accurate study drug accountability. To this end, the Sponsor’s Study Monitor will visit the study site at suitable intervals and be in frequent contact through verbal and written communication.  It is essential that the Sponsor’s 
Study Monitor have access to all documents, including study data, subject medical records, and eCRFs, at any time these are requested.   In turn, the Sponsor’s Study Monitor will adhere to all 
requirements for subject confidentiality as outlined in the ICF.  The PI and PIs staff will be 
expected to cooperate with the Sponsor’s Study Monitor, to be available during a portion of the monitoring visit to answer questions, and to provide any missing information. 
10.5 INSTITUTIONAL REVIEW BOARD  
In accordance with 21CFR  56, the protocol, advertisement, and ICF will be reviewed and 
approved by the IRB. The Sponsor will supply relevant material for the PI  to submit to the IRB 
for the protocol’s review and approval. Verification of the IRB unconditional approval of the 
protocol and the written ICF statement will be transmitted to the PI. 
 The IRB will be informed by the PI  of subsequent protocol amendments and of serious and 
unexpected AEs.  Approval for protocol amendments will be trans mitted in writing to the PI.  If 
requested, the PI will permit audits by the IRB and regulatory inspections by providing direct 
access to source data and documents. 
 The PI will provide the IRB with progress reports at appropriate intervals (not to exceed 1 year) 
and a Study Progress Report following the completion, termination, or discontinuation of the PIs  
participation in the study.  
10.6 INFORMED CONSENT  
Written informed consent for the study will be obtained from all subjects before protocol-specific procedures are carried out.   The ICF will be approved (along with the protocol) 
by the IRB and will be acceptable to the Sponsor.  The PI or designee will explain the nature of the study and the action of the test product.  The 
subjects will be informed that participation is voluntary and that they can withdraw from the study at any time.  In accordance with 21 CFR 50, the informed consent process shall be 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 71 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 documented by the use of a written ICF approved by the IRB and signed by the subject prior to 
protocol-specific procedures being performed.  The subject will sign two copies of the ICF.  On e copy will be given to the subject, and the other 
will be maintained with the subject’s records.  
10.7 RECORDS  
The results from Screening and data collected during the study will be recorded in the subject’s eCRF. To maintain confidentiality, the subjects will be identified only by numbers.  The completed eCRFs will be transferred to the Sponsor or designee. Copies of each e CRF will 
be retained by the PI. All source documents, records, and reports will be retained by the study 
site in accordance with 21 CFR 312.62(c).  All primary data, or copies thereof (e.g., laboratory records, case report forms [ CRFs], data 
sheets, correspondence, photographs , and computer records), which are a result of the original 
observations and activities of the study and are necessary for the reconstruction and evaluation of any study report, will be retained in the study site archives. 
10.7.1 ELECTRONIC CASE REPORT FORMS  
Electronic CRFs are to be completed using the Medidata RAVE EDC system. The site will 
receive training and have access to a manual for appropriate eCRF completion. Electronic CRFs 
will be submitted electronically to Covance and should be handled in accordance with 
instructions from Genentech/Covance.  All eCRFs should be completed by designated, trained examining personnel as appropriate.  
 The results from Screening and data collected during the study will be recorded in the subject’s 
eCRF. To maintain confidentiality, the subjects will be identified only by numbers. The PI  will 
ensure the accuracy, completeness, legibility, and timeliness of the data reported in the eCRF by providing an electronic signature. The completed eCRFs will be transferred to the Sponsor or designee. 
 In addition, at the end of the study, the PI  will receive subject data for the site in a readable 
format (e.g., a compact disc) that must be kept with the study records. 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 72 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 10.7.2 SOURCE DATA DOCUMENTATION  
Study Monitors will perform ongoing source data verification  and review to confirm that critical 
protocol data (i.e., source data) entered into the eCRFs by authorized site personnel are accurate, 
complete, and verifiable from source documents.  
 Source documents (paper or electronic) are those in which subject data are recorded and 
documented for the first time.  They include, but are not limited to, hospital records, clinical and office charts, laboratory notes, memoranda, subject diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies of transcriptions that are certified after verification as being accurate and complete, microfiche, photographic negatives, microfilm or magnetic media, X -rays, subject files, and records kept at the pharmacy, 
laboratories, and medico- technical departments involved in a clinical trial.  Source documents 
that are required to verify the validity and completeness of data entered into the eCRFs must never be obliterated or destroyed.  To facilitate source da ta verification  and review, the PI  and 
institution(s) must provide the Sponsor direct access to applicable source documents and reports for trial-related monitoring, Sponsor audits, and IRB  review.  The study site must also allow 
inspection by applicable health authorities.  
10.7.3 USE OF COMPUTERIZED SYSTEMS  
When clinical observations are entered directly into a study site’s computerized medical record system (i.e., in lieu of original hardcopy records), the electronic record can serve as the source document if the system has been validated in accordance with FDA requirements pertaining to computerized systems used in clinical research.  An acceptable computerized data collection 
system (for clinical research purposes) would be one that (1) allows data entry only b y 
authorized individuals; (2) prevents the deletion or alteration of previously entered data and provides an audit trail for such data changes (e.g., modification of file); ( 3) protects the database 
from tampering; and (4) ensures data preservation.  
 In collaboration with the Study Monitor, Genentech’s or Covance’s Quality Assurance group 
may assist in assessing whether electronic records generated from computerized medical record systems used at study sites can serve as source documents for the purposes of  this protocol.  If a 
site’s computerized medical record system is not adequately validated for the purposes of clinical research (as opposed to general clinical practice), applicable hardcopy source documents must be maintained to ensure that critical protocol data entered into the eCRFs can be verified.  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 73 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 10.7.4 STUDY MEDICATION ACCOUNTABILITY 
The recipient of study medication will acknowledge receipt by returning the appropriate 
documentation form indicating shipment content and condition.  Damaged supplies wi ll be 
replaced.  Accurate records of all study drug received at, dispensed from, returned to, and disposed of by the study site should be recorded by using the Drug Inventory Log.  Study drug will either be disposed of at the study site according to the st udy site’s institutional 
standard operating procedure or returned to Genentech with the appropriate documentation, as determined by the Sponsor.  If the study site is able to destroy study drug, the method of destruction must be documented. Genentech must evaluate and approve the study site’s drug destruction standard operating procedure prior to the initiation of drug destruction by the study site. 
10.7.5 DISCLOSURE OF DATA  
Subject medical information obtained by this study is confidential and may only be disclosed to third parties as permitted by the ICF (or separate authorization to use and disclose personal health information) signed by the subject or unless permitted or required by law.  Medical information may be given to a subject’s personal physician or other appropriate medical personnel responsible for the subject’s welfare for treatment purposes.  
 Given the complexity and exploratory nature of the analyses, data derived from exploratory biomarker specimens will generally not be provided to study PI s or subjects unless required by 
law.  The aggregate results of any conducted research will be available in accordance with the 
effective Sponsor policy on study data publication.  Data generated by this study must be available for inspection upon request by repr esentatives of 
the U.S. FDA and other regulatory agencies, national and local health authorities, Genentech monitors/representatives and collaborators, and the IRB for the study site, if appropriate. 
 Study data, may be submitted to government or other hea lth research databases or shared with 
researchers, government agencies, companies, or other groups that are not participating in this study.  These data may be combined with or linked to other data and used for research purposes, to advance science and pub lic health, or for analysis, development, and commercialization of 
products to treat and diagnose disease.  In addition, redacted clinical study reports and other summary reports will be provided upon request. 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 74 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 10.7.6 RETENTION OF RECORDS  
U.S. FDA regulations (21 CFR §312.62[c]) and the ICH Guideline for GCP require that records 
and documents pertaining to the conduct of this study and the distribution of investigational 
drug, including eCRFs, ICFs , laboratory test results, and medication inventory records, must be 
retained by the PI  for 2 years after the last marketing application approval in an ICH region or 
after at least 2 years have elapsed since formal discontinuation of clinical development of the study drug.  All state and local laws for retention of records  also apply.  No records should be 
disposed of without the written approval of the Sponsor.  Written notification should be provided to the Sponsor prior to transferring any records to another party or moving them to another 
location.  For studies conducted outside the United S tates under a U.S. IND, the PI must comply 
with the record retention requirements set forth in the U .S. FDA IND regulations and the 
relevant national and local health authorities, whichever is longer.  All primary data, or copies thereof (e.g., laboratory records, eCRFs, data sheets, correspondence, photographs, and computer records), which are a result of the original observations and activities of the study and are necessary for the reconstruction and evaluation of any study repo rt will be 
retained in the study site archives.  
10.8 REFERENCE TO DECLARATION OF HELSINKI/BASIC PRINCIPLES  
The study procedures outlined in this protocol will be conducted in accordance with the U .S. 
CFR governing Protection of Human Subjects (21 CFR 50), Financial Disclosure by Clinical PIs 
(21 CFR 54), IRBs  (21 CFR 56), IND Application (21 CFR 312), and Applications for FDA 
Approval to Market a New Drug (21 CFR 314), as appropriate.  As such, these sections of U .S. 
Title 21 CFR, along with the applicable ICH Guidelines, are commonly known as GCP, which are consistent with the Declaration of Helsinki.  
Clinical Protocol 
Covance Study 8398091 
SPONSOR AGREEMENT CONFIDENTIAL 
Protocol GP40957 
I have read the foregoing protocol and agree to the conduct of the study as described herein. 
Sravanthi Cheeti, B.Pharm., M.S. 
Clinical Pharmacologist 
Genentech, Inc. 
Final: 19 December 2018 
CPET Protocol Template, Version 11.0: 30 April2018 Date 
Page 77 of80 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 78 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 REFERENCES   
1. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 
2011;377:942-55. 
2. Bucchia M, Ramirez A, Parente V, et al. Therapeutic development in amyotrophic lateral 
sclerosis. Clin Ther 2015;37:668-80. 
3. Rilutek® Package Insert. Sanofi-Aventis Canada, Inc., 2016. Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020599s017lbl.pdf 
4. Ghosh AS, Wang B, Pozniak CD, et al. DLK induces developmental neuronal degeneration via selective regulation of proapoptotic JNK activity. J Cell Biol 2011;194:751-64. 
5. Pozniak CD, Sengupta AS, Gogineni A,et al. Dual leucine zipper kinase is required for excitotoxicity -induced neuronal degeneration. J Exp Med 2013;210:2553-67. 
6. Watkins TA, Wang B, Huntwork-Rodriguez S, et al . DLK initiates a transcriptional 
program that couples apoptotic and regenerative responses to axonal injury. Proc Natl Acad Sci USA 2013;110:4039-44. 
7. Hirai S, Cui DF, Miyata T, et al. The c-Jun N-terminal kinase activator dual leucine 
zipper kinase regulates axon growth and neuronal migration in the developing cerebral cortex. J Neurosci 2006;26:1 1992-2002 
8. Itoh A, Horiuchi M, Wakayama K, et al. ZPK/DLK, a mitogen- activated protein kinase 
kinase kinase, is a critical mediator of programmed cell death of motoneurons. J Neurosci 2011;31:7223-28. 
9. Le Pichon CE, Meilandt WJ, Domingues S, et al. Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Sci Transl Med 2017;9:403. 
10. GDC-0134 Investigator Brochure (IB), December 2018. 
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 79 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 APPENDIX A – CLINICAL LABORATORY EVALUATIONS  
Clinical  Chemistry  Panel  
(Fasted at least 8 hours):  Complete Blood Count:  Urinalysis:  
Alanine aminotransferase  
Albumin 
Alkaline phosphatase  
Aspartate aminotransferase  
Blood urea nitrogen  
Calcium 
Chloride 
Cholesterol  
Creatinine  
Creatine kinase (CK)/Creatine 
phosphokinase (CPK)  
Direct bilirubin  
Glucose 
Potassium  
Sodium 
Total bilirubin  
Total protein  
Triglycerides  
Uric acid 
 Hematocrit  
Hemoglobin  
Mean corpuscular hemoglobin  
Mean corpuscular hemoglobin 
concentration  
Mean corpuscular volume 
Platelet count  
Red blood cell (RBC) count  
RBC distribution width  
White blood cell (WBC) count  
WBC differential (absolute):  
Basophils  
Eosinophils  
Lymphocytes  
Monocytes  
Neutrophils  Bilirubin 
Color and appearance  
Glucose 
Ketones 
Leukocyte esterase  
Nitrite 
Occult blood  
pH and specific gravity  
Protein 
Urobilinogen Microscopic exam including bacteria, casts, crystals, epithelial cells, RBCs, and 
WBCs (if protein, leukocyte 
esterase, nitrite, or blood is 
positive) 
a 
Drug Screen:  Other Tests:  Coagulation Profile  
Including but not limited to the following:  
Alcohol (ethanol) c 
Amphetamines 
Barbiturates  
Benzodiazepines  
Cannabinoids (THC)  
Cocaine (metabolite)  
Methadone  
Opiates 
Phencyclidine  
Cotinine Hepatitis B virus core antibody b 
Hepatitis B surface antigen b 
Hepatitis C virus antibody b 
Human Immunodeficiency Virus 
antibody b 
Pregnancy test (serum qualitative)  
Follicle-stimulating hormone (FSH) b 
QuantiFERON® TB Gold 
Tuberculosis test b Prothrombin time (PT)  
Activated partial 
thromboplastin time 
(aPTT)/Partial 
thromboplastin time (PTT) 
International normalized ratio (INR) Fibrinogen  
 
a A microscopic examination will be performed at Screening. During other scheduled urinalysis  assessments, a 
microscopic examination will only be performed if protein, leukocyte esterase, nitrite, or blood is positive.  
b Measured at the Screening visit only. 
c Alcohol breath or urine testing will be performed at Check -in (Day -1) for both periods  only.  
Clinical Protocol  
Covance Study 8398091 CONFIDENTIAL  
Protocol GP40957 
 
 
Final:  19 December 2018  Page 80 of 80 
CPET Protocol Template, Version 11.0:  30 April 2018 APPENDIX B – APPROXIMATE MAXIMUM BLOOD VOLUME COLLECTED  
Numbe r of samples collected in each p art of the study  
 Sample Volume  
(mL)  Number of 
Samples  Total Volume  
(mL)  
Serology 7 1 7 
Clinical Laboratory Evaluations  (including serum 
pregnancy and serum FSH)  12.5 5 62.5 
Coagulation  3 3 9 
Tuberculosis (Quantiferon® TB Gold)  4 1 4 
PK Samples  4 31 124 
WGS Sample  6 1 6 
Total  per part  212.5 
FSH = follicle -stimulating hormone; PK = pharmacokinetic; TB = tuberculosis;  WGS = whole genome sequencing.  
 
Note:  Additional samples may be drawn for safety purposes. 
 If subjects participate in both parts of the study, the total blood volume will be approximately double that indicated in the table (~425 mL). 